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Definitions 
 
‘Acceptance’ Score Calculated overall scores out of 100 from 
‘acceptance’ sections of the survey used in this 
research to determine each participant’s 
‘acceptance’ toward the use of micronutrients as an 
alternative treatment for mood disorders. 
Acceptance ‘towards the use of 
micronutrient treatment in 
people under the age of 18’ 
score 
Calculated averages out of five from the final 
section of the survey used in this research to 
determine each participant’s ‘acceptance’ toward 
the use of micronutrients as an alternative treatment 
for mood disorders in people under the age of 18. 
Alternative Treatment Any treatment that is not a form of psychotherapy, 
counselling, professional talking therapy or any 
prescribed antidepressant or anti-psychotic 
medication. 
Cognitive Behavioural Therapy A psychotherapeutic approach addressing 
dysfunctional emotions, behaviours, and cognitions 
through a goal-oriented, systematic process. 
Conventional Treatment Any treatment for a mood disorder that is a form of 
psychotherapy, counselling, any kind of 
professional talking therapy and/or any prescribed 
medication such as anti depressants or anti 
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psychotics. 
Dietary Supplement (also 
known as a food supplement) 
Preparation intended to supply nutrients, (such as 
vitamins, minerals, fatty acids or amino acids) that 
are missing or not consumed in sufficient quantity 
in a person's diet. 
EMPowerplus A micronutrient treatment consisting of 16 
minerals, 14 vitamins, 3 amino acids, and 3 
antioxidants. 
Healthcare and/or medical 
practitioner 
Including but not limited to psychiatrists, family 
doctors or General Practitioners, other medical 
doctors, psychologists, nurses, social workers, 
counsellors or psychotherapists. 
‘Healthy Lifestyle’ Score Calculated overall scores out of 80 from health 
sections of the survey used in this research to 
determine each participant’s level of importance 
indicated to leading a healthy life. 
Micronutrients Dietary multivitamins, minerals and amino acids. 
Mood Disorder A depressive disorder (including atypical 
depression, melancholic depression, psychotic 
major depression, catatonic depression, postpartum 
depression, seasonal affective disorder, dysthymia 
and/or depressive disorder not otherwise 
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specified) or bipolar disorder (including bipolar I, 
bipolar II, cyclothymia and/or bipolar disorder not 
otherwise specified). 
Multivitamins A dietary supplement containing all or most of the 
vitamins that may not be readily available in the 
diet. 
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Abstract 
 
The World Health Organisation predicts that by 2020 depression will be the second highest 
cause of death and disability in the world (World Health Organisation, 2010). Selective 
serotonin reuptake inhibitors (SSRIs) have been found to be the most suitable antidepressant 
for first-line treatment of a mood disorder (National Institute for Health and Clinical 
Excellence, 2004), but less than half of all individuals achieve complete remission after 
therapy with a single antidepressant. Others display partial or intolerant responses to 
treatment (Nemeroff & Owens, 2002). This emphasises a need to develop alternative 
treatment options. There is evidence that micronutrients have fewer side effects than 
antidepressants (Dalmiya, Darnton-Hill, Schyltink & Shrimpton, 2009). Kaplan, Crawford, 
Field and Simpson (2007) suggest that errors in metabolism may result in unstable mood, 
leading to possible mood disorders. Mutation of metabolism is correctable by giving the 
malnourished individual additional vitamins thereby correcting metabolism and creating a 
more stable mood. An online survey completed by 661 participants (141 males, 520 females) 
assessed acceptance levels towards the use of micronutrients as an alternative treatment for 
mood disorders. As predicted, healthcare and medical professionals scored lower in 
acceptance (t(659)=3.12, p=0.002) and people who lead healthy lifestyles scored higher in 
acceptance (r=0.105, n=658, p <0.05). There were no significant effects of gender (t(659) 
=1.74, p=0.082), experience with mood disorders (F(3, 657)=0.86, p=0.46) or low household 
incomes (r=-0.066, n=661, p<0.05). Treatment users and providers alike seek more 
knowledge about the effectiveness of micronutrients and acceptance of micronutrients is 
largely granted on the basis of a combination treatment with conventional methods. The study 
is limited by an overrepresentation of females in the sample. 
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Introduction 
 
Conceptualisation of Mood Disorders 
‘Mood disorder’ is an expression for a group of diagnoses as classified by the Diagnostic and 
Statistical Manual IV-TR (DSM-IV-TR) (American Psychiatric Association, 2000).  
Pioneering British psychiatrist Henry Maudsley (1835-1918) proposed the all-encompassing 
category for these diagnoses as ‘affective disorders’. This was later replaced by ‘mood 
disorders’, with ‘affective disorders’ referring to a persons’ external observable expressions 
and ‘mood disorders’ referring to ones underlying emotional state (Bynum, Porter & Shepard, 
1988). The category of ‘mood disorders’ comprises bipolar disorders and depressive 
disorders. Bipolar disorders are divided into four separate disorders, while depressive 
disorders are divided into ten (American Psychiatric Association, 2000). The depressive 
disorders encompass atypical depression, melancholic depression, psychotic major 
depression, catatonic depression, postpartum depression, seasonal affective disorder, 
dysthymia, depressive disorder not otherwise specified, recurrent brief depression and minor 
depressive disorder. The bipolar disorders encompass bipolar I, bipolar II, cyclothymia and 
bipolar disorder not otherwise specified (American Psychiatric Association, 2000).  
 
Subtypes of Depressive Disorders and Comorbidity 
Ten subtypes of depressive disorders are characterised by the DSM IV-TR (American 
Psychiatric Association, 2000).  
Atypical depression is characterised by mood reactivity and positivity, significant 
weight gain or increased appetite, excessive sleep, a sensation of heaviness in limbs and 
social impairment due to hypersensitivity.  
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Melancholic depression is characterised by a loss of pleasure in many or all activities 
(anhedonia), failure to react positively to pleasurable stimuli, a more depressed mood than 
that of grief or loss, an exacerbation of symptoms in the morning, early waking, excessive 
weight loss and excessive guilt.  
Psychotic major depression (psychotic depression) is a major depressive episode of 
melancholic nature. The person may experience delusions which are fixed false beliefs that 
are resistant to reason or confrontation with actual fact (Garety, 1985) or hallucinations, 
sensory experiences that do not exist outside of the mind (Liester, 1998). 
Catatonic depression is a rare and severe form of major depression that disturbs motor 
behaviours. The person is mute, may be immobile or exhibit purposelessness, even bizarre 
movements. These movements may also be found in people experiencing schizophrenia.  
Postpartum depression refers to the intense depression experienced by women after 
giving birth, usually setting in within three months of labour.  It can cause significant 
hardship and impaired functioning in all aspects of life. Difficulty in relationships with 
spouses, family members or the new born may arise.  
Seasonal affective disorder is a seasonal pattern of depression, usually with depressive 
episodes coming on in the autumn or winter, resolving in spring. The diagnostic criteria are 
reached if at least two episodes of depression have been experienced in colder months and at 
no other times during a two year period or more. This subtype typically affects females more 
often than males (Leibenluft, Hardin & Rosenthall, 1995).  
Dysthymia is a chronic mood disturbance where a person experiences a low mood 
nearly every day for a span of two years or longer. Symptoms are slightly weaker than that of 
major depression, although people with dysthymia are vulnerable to episodes of major 
depression (also known as ‘double depression’). 
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Depressive disorder not otherwise specified is a category for impairing depressive 
disorders that do not fit the criteria for other specific depressive disorders. This category 
encompasses both recurrent brief depression (RBD) and minor depressive disorder. RBD is 
distinguished from major depressive disorder by its duration. Depressive episodes occur 
usually once a month, with individual episodes lasting typically less than three days. Criteria 
to meet diagnosis for RBD specify that episodes need to occur over at least one year (in 
females this needs to be independent of menstrual cycles). Minor depressive disorder refers to 
depression that does not meet the criteria for major depression but the person experiences at 
least two of the same symptoms for two weeks or longer (American Psychiatric Association, 
2000). 
Depressive disorders are often associated with other psychiatric disorders, notably 
anxiety disorders. Prominent comorbid anxiety disorders include panic disorder, generalised 
anxiety disorder, social anxiety disorder, obsessive-compulsive disorder and Post-Traumatic 
Stress Disorder (Nemeroff & Owens 2002). 
 
Subtypes of Bipolar Disorder & Comorbidity 
Bipolar disorder was originally known as ‘manic depression’. It is identified by alternating 
episodes of mania, a state of abnormally elevated or irritable mood and/or energy, and 
depression (American Psychiatric Association, 2000). According to the DSM IV-TR subtypes 
of bipolar disorder are as follows: 
 Bipolar I is classified by the history of one or more manic episodes or a mix of manic 
and depressive episodes. A depressive disorder is not required to meet criteria for diagnosis, 
but depressive episodes are often present.  
 Bipolar II is classified as recurrent irregular hypomanic (persistent and all-
encompassing elevated mood and/or energy) and depressive episodes. 
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 Cyclothymia consists of recurrent hypomanic and dysthymic episodes, but no full 
major depressive or manic episodes. 
 Bipolar disorder not otherwise specified is similar to depressive disorder not 
otherwise specified in that the individual experiences some symptoms within the bipolar 
spectrum, such as depressive and manic symptoms, but does not meet the complete criteria 
for any of the three bipolar diagnoses in the DSM-IV-TR described above (American 
Psychiatric Association, 2000). 
 In the National Comorbidity Survey conducted in the United States in 1990-1992 and 
2001-2003, it was found that 95% of respondents diagnosed with a form of bipolar disorder 
also met the criteria for three or more lifetime psychiatric disorders. These included anxiety 
disorders, substance use disorders, personality disorders or attention deficit hyperactivity 
disorder (ADHD) (Martin, 2011).  
  
Contributing Factors to the Onset of a Mood Disorder 
The etiology of mood disorders, as with all mental disorders, is complex and indefinable. 
Interactions of differing environmental exposures, life events, susceptibilities, genetic, 
developmental, biochemical, nutritional, endocrine and psychosocial factors all contribute to 
onset. This complexity explains the differing degrees to which people are affected and able to 
be treated (Kendler, Kuhn & Prescott, 2004).  
Table 1 is taken from Bruder-Costello, Warner and Talati (2007) and Brown, Craig, 
and Harris (2007) and combines the risk and resilience factors for depressive disorders: 
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Table 1 
Risk Factors and Resilience Factors for Depression 
 
Common Risk Factors 
(which could lead to vulnerability) 
 
 
Resilience Factors 
(protective in the presence of risk factors) 
 
Parental history of depression 
 
Good parenting including emotional warmth 
and cognitive stimulation 
 
Difficult temperament as a child: displays 
behaviour such as impulsiveness, shyness, 
difficulty in concentration, easily upset, poor 
task persistence, irritability 
 
Easy temperament as a child: displays such 
behaviour as adaptability in novel situations, 
sociability, has a low intensity of reactions. 
Attachment difficulties/parental neglect Good peer relationships 
  
Family discard: tension between parental 
figures, arguments or fighting (often 
preceded by financial problems) 
Suitability in love relationships 
 
Previous depression/anxiety in adulthood 
 
Has coped with past difficulties well 
 
Ruminating over negative circumstances 
 
 
 
 
The recognition of bipolar disorder may take years based on presenting symptoms of the 
individual. On average, however, many people will be diagnosed before the age of 30 
(Gillberg, Hellgren, & Gillberg, 2006). Family and twin studies support the position that the 
role of genetic influence in the onset of bipolar disorder is high. There is a likely interaction 
between genetic predisposition and environmental influences, including stressful life events, 
as is the case with depressive disorders. Individuals presenting with cyclothymia or thyroid 
dysfunction are also at particular risk for bipolar disorder (Rush, 2003). 
 
Rates of Mood Disorder and At Risk Populations  
The New Zealand Mental Health Survey was undertaken between 2003 and 2004 and used 
structured diagnostic interviews to generate DSM-IV diagnoses for nearly 13,000 New 
MICRONUTRIENT TREATMENT IN MOOD DISORDERS 
 
6 
 
Zealanders 16 years and over. The survey revealed that 21% of people had experienced a 
mental disorder in the 12 months prior, 20% of which were mood disorders. The survey also 
indicated the lifetime prevalence of major depressive disorder to be 16%, bipolar to be 4%, 
dysthymia to be 2% or any mood disorder (including people experiencing more than one 
disorder) to be 20% for New Zealand adults (Oakley-Brown, Wells, Scott & McGee, 2006). 
The following sections discuss at-risk populations in New Zealand for mood disorders. 
 
Female individuals 
According to the 2006 New Zealand Mental Health Survey, males have prevalence for a 
major depressive disorder of 11.4%, while females exceed this with a prevalence of 20.3% 
(Oakley-Brown, et al. 2006). A study by ‘Next’ Magazine in 2005 collected 4720 survey 
responses from females based on their health. Two out of every five of the women had been 
diagnosed with a depressive disorder. More than 30% of depressed respondents claimed that 
they did not receive adequate support for their symptoms. Respondents ranked family, 
friends, their doctor and their partner as most supportive in that order (Schumacher, 2005).  
The World Health Organisation reported in 1990 that men and women appear to be 
equally affected by bipolar I (Murray & Lopez, 1996), with the first manic episode usually 
occurring in a person’s early twenties (Kessler, McGonagle, Zhao, Nelson, Hughes & 
Eshleman, 1994). Males with bipolar II typically report the experience of a depressive 
episode for every hypomanic episode, with females reporting more depressive episodes 
(National Institute of Mental Health, 2002). 
 
Adolescent individuals 
Mood disorders are among the most experienced mental disorders by people up to the age of 
18 in New Zealand, alongside anxiety disorders, conduct disorders and substance abuse 
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(Fergusson, Horwood & Lynskey, 1997). The Dunedin Health and Development Study 
(1973) determined an 18% prevalence rate of mental disorders experienced by 11 year-olds, 
rising to 35% in 18 year olds (McGee, Feehan & Williams, 1996.) It is common for 
adolescent depression to follow childhood anxiety, commonly revealing a genetic 
predisposition as concluded in a study conducted by Mineka, Watson and Clark in 1998.  
The University of Auckland Adolescent Health Research Group discovered that 
female secondary school students were twice as likely as males to report depressive 
symptoms deemed serious enough to require professional intervention (University of 
Auckland Adolescent Health Research Group, 2003). Furthermore, the Youth 2000 survey 
found that Maori female taitamariki (youth) were almost twice as likely to have significant 
depressive symptoms as male taitamariki (as measured by the RADS depression scale) 
(University of Auckland Adolescent Health Research Group, 2003).  
 
Older individuals 
A study completed in 2003 in New Zealand found that older lonely males between 65 and 89 
scored higher on the Geriatric Depression Scale, indicating a significant relationship between 
depression and social isolation. Researchers additionally found that depression is often a 
response to declining health and impairment in older adults (Alpass, 2003). Other risk factors 
of depression among older adults include bereavement and elder abuse (Fallon, 2006).  
 
Homosexual, lesbian or bisexual individuals 
An individual’s sexuality may be a risk factor for mood disorders. King and Nazareth (2006) 
found evidence to suggest increased vulnerability to psychological distress and/or alcohol 
abuse among lesbian, gay and bisexual adults in comparison to heterosexuals. Furthermore, 
the Christchurch Health and Development study discovered that the risk for major 
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depression, conduct disorder, nicotine dependence and suicidal ideation and suicide attempts 
increased four-to-six fold between 14 and 21 years of age in homosexual, lesbian and 
bisexual individuals (Fergusson, Horwood, Beautrais, 1999). Collingwood (2011) adds that 
discrimination may contribute to a higher risk of depression for these individuals. 
 
New and expectant mothers 
Pregnancy and childbirth are times of psychological change for women. It is often a time of 
sleep disturbance, tiredness, loss of libido and feelings of anxiety about the newborn 
(National Institute for Health and Clinical Excellence, 2007). As stated, stressful life events 
are a potential risk factor for the onset of mood disorders, also increasing the risk of a pre-
existing disorder (Weinberg, Tronick, 1998).  
A survey study undertaken in Auckland in 2005 found that 30% of New Zealand 
European/Caucasian females at 4 months postpartum were experiencing depressive 
symptoms, yet only 13% of these women were seeking treatment. The researchers concluded 
that the prevalence of postnatal depression in urban New Zealand is slightly higher than that 
of the worldwide average, yet for the most part remains untreated (Thio, Oakley-Browne, 
Coverdale & Argyle, 2006). Prior to this, Christchurch researchers concluded a prevalence 
rate of 20% of postnatal depression in females, with 13% experiencing significant depression 
and 7% having a borderline level of symptoms with only 6% of the women recognising their 
symptoms as being characteristic of depressive disorders (McGill, Burrows, Holland, Langer 
& Sweet, 1995). Finally in a 2006 New Zealand study, the rates of post natal depression 
(using a screening questionnaire) amongst Pasifika women ranged from 7% amongst Samoan 
women to 30% in Tongan women (Foliaki, Kokaua, Schaaf &Tukuitonga, 2006). 
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Maori and Pacific Island individuals 
Maori are three times more likely than non-Maori to be experiencing a depressive disorder 
(Magpie Research Group, 2005). It has been identified that regardless of income, occupation, 
or level of education, Maori have poorer health status than non-Maori (Ministry of Health, 
2006). Suicide rates for Maori are 17.9 per 100,000 versus 12 per 100,000 for non-Maori 
(Ministry of Health, 2007). 
 Pacific people including Samoan, Tongan and Cook Islanders additionally experience 
a high prevalence of mood disorders and suicidal behaviour in New Zealand (Polotu-
Endemann, Annandale & Instone, 2004). The New Zealand Mental Health Survey found an 
overall higher rate of suicidal ideation (4.5%) among Pacific peoples and attempts (1.2%) for 
the previous 12 months than non-Pacific peoples in New Zealand (Foliaki et al. 2006). The 
New Zealand Ministry of Health estimates that 11,000 Pacific people can expect to 
experience mood disorders and generalised anxiety and that these disorders are more likely to 
affect Pacific Island females (Ministry of Health, 2005). The prevalence of mood disorders 
was found to be lower among Pacific people born in the Pacific Islands than those born in 
New Zealand, and only 25% of Pacific peoples experiencing a mood disorder sought out 
professional help compared with 58% of non-Pacific peoples (Foliaki, et al. 2006). 
 
Asian individuals 
In 2003, 162 Chinese migrants over 55 were interviewed using the Geriatric Depression 
Scale, with 26% meeting criteria for some type of depressive disorder. Results from the study 
indicated more frequent visits to the doctor, lower emotional support and increased risk for 
depression than  non-Chinese due to issues of assimilarion into the New Zealand culture 
(Abbott, Wong, Giles, Wong, Young & Au, 2003). Another study conducted a literature 
review which concluded that Asian populations tend to present (and therefore be treated) later 
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to mental health professionals due to a strong cultural stigma against mental illness (Ho, Au, 
Bedford & Cooper, 2003). 
 
Displaced individuals 
Refugees experiencing the stress of adapting to a new culture are at risk for mood disorders. 
Female refugees within smaller migrant communities of New Zealand (eg Vietnamese or 
Indonesian) have been found to have high mental health needs (Ho et al. 2003). Refugees 
also often have specific mental health needs associated with torture (Ho et al. 2003). 
Additionally there have been found to be high levels of depression among older Chinese 
immigrants (Ho et al. 2003).  
 
Inmates 
A 1999 psychiatric survey of New Zealand prisons concluded that inmates have significantly 
higher rates of bipolar disorder and major depression than non-inmates (Ministry of Justice, 
Ministry of Health, 1999). The survey also concluded that one quarter of all inmates had 
experienced a major depressive disorder and that 90% of those experiencing major mental 
illness also had a substance abuse disorder (Ministry of Justice, Ministry of Health, 1999). 
 
Pathophysiology of Mood Disorders 
The precise biology of mood disorders remains unclear; however, advances in neuroscience 
and areas of biology and brain imaging help to improve understanding of mood disorders 
(Nemeroff & Owens, 2002). What has been identified is that during the course of a mood 
disorder three primary neurotransmitters are implicated: dopamine, norepinephrine and 
serotonin. These operate within structures of the brain (the limbic system and hypothalamus) 
that regulate emotions, sleep, stress levels, sexuality and appetite (Harrison, 2002). 
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Treatments for mood disorders such as antidepressants can be investigated to 
identify how they work in the brain thus furthering the understanding of the biological causes 
of mood disorders. It is believed that such treatments are effective because they regulate the 
specific amount of implicated neurotransmitters in the brain. However, the roles that 
neurotransmitters play in the onset of mood disorders is still not entirely clear (Beck, Alford, 
2009).  
 The endocrine system is implicated in the biological causation of mood disorders. 
This system is made up of small glands within the body that create and release hormones into 
the blood. These hormones regulate sexual development and stress reaction (Levinson, 2006). 
Hormonal irregularities may be related to depressive symptoms (Tichomirowa, Keck, 
Schneider, Paez-Pereda, Renner, Holsboer & Stalla, 2005).  
 
Treatments for Mood Disorders 
A furthered understanding of the biological causes of mood disorders has been achieved 
through the use of various treatments. Some therapy based treatments include Adlerian 
Therapy, behavioural therapy, existential therapy, Gestalt therapy, person-centered therapy, 
psychoanalytic therapy, rational-emotive therapy, reality therapy, cognitive behavioural 
therapy (CBT) and family systems therapy (Segal, Mark & Teasdale 2002). 
CBT focuses on human thought, as many people with psychological disorders, 
particularly depressive, anxiety, and sexual disorders have been found to display 
dysfunctional assumptions and thoughts (Beck, 1983). Cognitive therapy has been found to 
be effective for treating depression, and moderately effective for anxiety problems (McLeod, 
1998). 
In addition to CBT, there are some commonly prescribed medications for mood 
disorders including antidepressants. Antidepressants come in various forms, the most 
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common being Selective Serotonin Reuptake Inhibiters (SSRI’s). Unless there are specific 
reasons for choosing another type of antidepressant, it has been found that the most suitable 
antidepressant for first-line treatment of a mood disorder is a SSRI (National Institute for 
Health and Clinical Excellence, 2004). This is because the relative safety of SSRIs in an 
overdose makes them preferable to the alternative, tricyclic antidepressants or 
monoamineoxidase inhibitors (Gelenberg & Hopkins, 2007). SSRIs prevent the reuptake of 
the neurotransmitter serotonin back into the nerve endings, associated with the onset of mood 
disorders. Some currently available SSRIs include fluoxetine, citalopram, sertraline, 
paroxetine and escitalopram (Jacobson & Jacobson, 2001).  
 
Limitations of treatment 
The successful treatment of a mood disorder is highly variable. Variables include 
compliance of the individual with treatment and the severity of the experience (Jefferson, 
2000). The Ministry of Health in British Colombia produced a guideline in 2004 containing 
issues surrounding the treatment of mood disorders, many of which are also present in New 
Zealand. These issues include a stigma associated with mood disorders leading to lack of help 
sought; inadequate duration or dosage of antidepressants; inadequate education received by 
the individual about the nature of mood disorders; limited access to mental health 
practitioners and lack of treatment maintenance (Ministry of Health British Columbia, 2004). 
Available antidepressant drugs are safe and effective, but less than half of all individuals 
achieve complete remission after therapy with a single antidepressant, while others may 
display partial or intolerant responses to treatment (Nemeroff & Owens, 2002).  
A 2005 literature review (Goldberg & Ghaemi, 2005) looked at the risks when using 
antidepressants and antipsychotics to treat bipolar disorders. It was reported that individuals 
with a rapid cycling form of bipolar showed worsening of rapid cycling with the use of 
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antidepressants, with a possibility of exacerbating depressive symptoms in bipolar I and 
increasing antidepressant intolerance in bipolar II.  Furtermore, antidepressants have the 
potential to aggravate bipolar mania symptoms and may accelerate cycling and heighten 
suicide risk in adolescents with a bipolar disorder.  
A 2007 study outlined some limitations of contemporary antidepressants in the 
treatment of depressive disorders (Papakostas, 2007). Some side effects noted in the use of 
antidepressants are distress, discomfort, disability, and morbidity. The authors recommend 
the development of a treatment that has lower incidences of side effects or to use treatment 
strategies that will alleviate side effects to improve the standard of care for mood disorders. It 
has also been reported that between 30% and 40% of individuals taking antidepressants 
develop some degree of sexual dysfunction (Rothschild, 2000). Additionally, it was found in 
2004 that the use of SSRIs and new antipsychotics is associated with adverse cardiac and 
vascular effects, a significant hazard, particularly for those with cardiovascular disorders 
(Pacher & Kecskemeti, 2004). SSRIs are also reported to lead to gastrointestinal side effects 
including nausea and diarrhoea; central nervous system side effects including anxiety, 
insomnia, sedation and nightmares; bleeding disorders such as bruising and gastrointestinal 
bleeding; Serotonin Syndrome causing extreme agitation, hyperthermia, delirium or seizures 
and Discontinuation Syndrome causing dizziness, nausea, weakness, irritability and headache 
(Khawam, Laurencic & Malone, 2006). 
Finally, there are some limitations in using CBT. CBT is not easily accessed by all 
who seek it due to high cost (Marchand, Germain, Reinharz, Mainguy & Landry, 2004). 
There are also ethical considerations. CBT is a directive therapy aimed at changing 
cognitions, in some cases forcefully. Additionally, the cognitive model may be narrow in 
scope (McCleod, 2008). As with any treatment, questions also exist regarding the long-term 
effectiveness of CBT (Butler, Chapman, Forman & Beck, 2006). 
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These issues of low compliance, incorrect dosage, inadequate education, low access to 
mental health practitioners, lack of treatment maintenance, low remission rates, intolerant 
responses and side effects when using conventional treatments highlight a need to develop 
alternative treatment options in the treatment of mood disorders. 
 
Complementary and alternative treatment 
It is not uncommon for people with mood disorders to try and manage the illness themselves. 
Complementary and alternative medicine (CAM) is defined as those “medical and health care 
systems, practices, and products that are not presently considered to be part of conventional 
medicine” (National Center for Complementary and Alternative Medicine, 2002). As 
discussed, conventional treatments may often be unavailable or ineffective. Chong and 
colleagues (2008) concluded that the use of CAM is not uncommon. Data was collected from 
patients in medical wards at a Brunei hospital based on their use of CAM. Of their 568 
participants, one fifth had used CAM in the past 12 months.  
According to Beyond Blue, evidence-based CAM for depressive disorders may 
include but are not limited to St Johns Wort (Hypericum perforatum), physical exercise, self-
help books involving CBT and light therapy (Beyond Blue Australia, 2008). A study 
conducted in 2005 based on data from 32 million adults concluded that common forms of 
CAM in the United States of America in 2002 were herbal therapy (18.6%), relaxation 
(14.2%) and chiropractic techniques (7.4%) (Tindle, Davis, Phillips & Eisenberg, 2005). It 
was also reported in a New Zealand study (Nicholson, 2006) that of 1043 people surveyed, 
one in three people had used vitamins and minerals as a form of CAM. Similarly, it was 
found in a 2008 study that of 568 participants surveyed about their use of CAM, of those who 
had used CAM in the last 12 months, 35.8% had used vitamin and mineral supplements. The 
most common reasons for using CAM in the sample were anxiety, depression and insomnia 
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(Chong, Rajendran & Wint, 2008). Additionally, in a national Australian sample, 57% of 
individuals regarded vitamins, minerals, tonics or herbal medicines as potentially helpful for 
treating depression (Jorm, Christensen, Griffiths & Rodgers, 2002). With such high reports of 
vitamin and mineral supplement use of CAM, it seems that there may be popularity for 
vitamins and minerals as a potential alternative form of treatment for mood disorders. 
 
Micronutrients and Mood 
There is a significant breadth of knowledge on the benefits of vitamin and mineral intake yet 
there is little discussion on how these work on brain mechanisms. This leaves open an area of 
research in need of further investigation. There may be potential benefits in using 
multivitamins or micronutrients (vitamins, minerals and amino acids) when treating mood 
disorders.  
Kaplan and colleagues (2007) reviewed literature on the effects of vitamins and 
minerals on mood. One formula reviewed was a 36-ingredient micronutrient containing 16 
minerals, 14 vitamins, 3 amino acids and 3 antioxidants named EMPowerplus. The review 
described the effect that the nutrients had on neurotransmitters in the brain. Four alternate 
models examined how the use of micronutrient supplements such as EMPowerplus may be 
able to relieve symptoms of mood disorders (Kaplan, Crawford, Field & Simpson, 2007).   
The first model presented by Kaplan and colleagues (2007) suggests that errors in 
metabolism may result in unstable mood, leading to possible mood disorders. Mutation of 
metabolism is correctable by giving the malnourished individual additional vitamins, thereby 
restoring the deficiencies, correcting metabolism and creating a more stable mood.  
A second model suggests that deficient methylation processes may lead to unstable 
mood. Methylation reactions activate enzymes and genes in our brains, and regulate protein 
that genes create. Correct neurotransmitter synthesis is not possible without methylation. It is 
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not certain where the direction of causality lies, deficiencies in methylation processes may 
result in mood disorders, or mood disorders may lead to deficiencies in methylation 
processes. In either instance it seems logical that methylation processes need to be corrected 
in order for mood to remain stable. 
The next model presented suggests that nutrient deficiency may result in unstable 
mood by way of gene expression alteration. Nutrients have been shown to alter gene 
expression, as displayed in a study completed in 2003 (Waterland & Jirtle, 2003).  It was 
found that nutrient supplements given to mice altered the expression of certain genes. For this 
reason it may be possible that nutrient deficiencies alter the expression of genes that may 
influence mood. 
The final model presented by Kaplan and colleagues (2007) explains that long-term 
insufficiency of particular nutrients may cause a development of unstable mood over a long 
period of time. For this reason, the use of a daily micronutrient would be required to maintain 
a stable mood.  
The models put forward by Kaplan and her colleagues make a convincing argument 
for micronutrients as a worthwhile alternative treatment to mood disorders. A brief look into 
how particular vitamins and minerals work with certain neurotransmitters in the brain further 
adds to this evidence base.  
Calcium plays an important role in sending messages between different cells (Gilroy, 
Read & Trewavas, 1990); iron has an important role in ensuring that enough oxygen is in the 
brain (Gutteridge, 1992); magnesium is involved in over 300 chemical reactions in the human 
body (Seelig, 1994) and zinc is involved in metabolism (Cuajungco & Lees, 1997). With 
regards to some of the B vitamins; vitamin B9 (folic acid) is known to heighten serotonin 
function which is associated with depression (Malouf, Grimley & Areosa, 2004); vitamin 
B12 which plays a part in synthesis of monoamine neurotransmitters (Bottiglieri, Laundy, 
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Crellin, Toone, Carney & Reynolds, 2000) is also associated with depression and vitamin B6, 
and is involved in the synthesis of a wide variety of neurotransmitters, namely those 
associated with anxiety and depression (Pietz, Benninger, Schäfer, Sontheimer, Mittermaier 
& Rating,1993).  
With having an established theory as to how vitamins and minerals function in the 
brain, it is important to evaluate how vitamins and minerals influence mood disorders and 
other psychiatric symptoms. There have been a number of studies done on the use of 
micronutrients and their effect on psychiatric symptoms.  
Various micronutrient supplements have been used in double-blind randomised 
control trials, resulting in changes in mood.  In 1992, 1081 healthy males between the ages of 
17 and 29 trialled a micronutrient formula containing B1, B2, B6, B9, B12, vitamin C and 
vitamin E for eight weeks. Males with previous nutrient deficiencies showed significant 
clinical improvements in fear, nervousness and depressive symptoms (Heseker, Adolf, 
Eberhardt & Hartmann, 1992). In 1995, 119 male and 90 female healthy university students 
(between 17-27 years) used a micronutrient formula containing B1, B2, B3, B6, B9, B12, 
vitamin A, C, D and H for one year.  Both males and females reported feeling more 
agreeable, composed and having better mental health compared to placebo groups (Benton, 
Shan & Hardy, 1995).  
Double-blind randomised control trials were additionally conducted in 2007 and 2008 
on non-healthy participants. Vitamins B1, B2, B3, B5, B6, B9, B12, vitamins C, D, E and H, 
calcium, copper, iron, magnesium, manganese, phosphorus, potassium, selenium and zinc 
were given to 225 hospitalised older patients over 65 experiencing varied symptoms of 
depression. The trial ran for six weeks. Interestingly however, placebo and micronutrient 
groups differed on depression scores at six months. Micronutrient effects were observed in 
non-depressed participants, those with mild symptoms of depression and those with severe 
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depression (Gariballa and Forster, 2007). In 2008, a micronutrient treatment containing B1, 
B2, B3, B6, B9, B12, vitamins A, C, E and H, calcium, copper, iron, magnesium, manganese, 
selenium and zinc was trialled with 59 nursing home residents. There were no effects on 
anxiety scores, however there was a significant reduction in depression scores compared to 
the placebo group which showed no change (Gosney, Hammond, Shenkin & Allsup, 2008).  
Two more double-blind randomised control trials were conducted in 2009 and 2010.  
422 healthy females in Guatemala (between 15-49 years) were trialled for 12 weeks using a 
micronutrient formula containing B9, B12, iron and zinc in 2009. Almost half of the 
participants had depression scores above the clinical cut-off before the trial, with these scores 
lowering by the end of the trial (Nguyen, Grajeda, Melgar, Marcinkevage, DiGirolamo, 
Flores & Martorell, 2009). In 2010, 273 post-stroke survivors with an average age of 63 using 
a micronutrient formula containing B6, B9, and B12. The results demonstrated a lower risk of 
major depression when compared to the placebo (Almeida, Alfonso, Hankey & Flicker, 
2010).  
Finally, a trial was conducted in 2011 with 50 healthy men between 50-69 years using 
a micronutrient formula including B1, B2, B5, B6, B9, B12, vitamin E, bioflavonoids, calcium, 
choline bitartrate, inositol, iron, lysine hydrochloride, magnesium, tyrosine and potassium. 
Compared with the placebo, participants experienced an improvement in alertness and 
general daily functioning, and showed a reduction in overall total anxiety and depression 
scores (Harris, Kirk, Roswell, Vitetta, Sali, Scholey & Pipingas, 2011). 
The aforementioned studies demonstrate a convincing argument for the effect of 
micronutrient treatments on changes in mood. These results are limited however, due to their 
sampling of non-depressed participants. 
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Micronutrients and Mood Disorders 
The following studies demonstrate the effects of micronutrients in participant samples 
experiencing mood disorders. 
 A study completed by Kaplan and colleagues in 2001 treated 11 people diagnosed 
with bipolar disorder between 19-46 years of age on psychotropic medications with 
EMPowerplus. After a six month open-label trial, the need for psychotropic medications 
decreased by 50% and symptom reduction ranged from 55%-66% (Kaplan, Simpson, Ferre, 
Gorman, McMullen & Crawford, 2001). An open-label trial using EMPowerplus in bipolar 
participants was also conducted in 2001. Results found a clinical improvement in bipolar 
symptoms in 19 of the 22 adolescent and adult participants (Popper, 2001). 
A 2004 study focussed on children with mood and behavioural problems using 
EMPowerplus. Nine children completed the open-label trial and their parents completed the 
Child Behaviour Checklist (CBCL), Youth Outcome Questionnaire (YOQ), and Young 
Mania Rating Scale (YMRS). After eight weeks on the nutrient supplement the children 
showed significant improvement on seven of the eight CBCL scales, the YOQ, and the 
YMRS (Kaplan, Fisher, Crawford, Field, & Kolb, 2004).   
A 2008 study looking at the self-help interventions used by people experiencing 
depressive symptoms trialled various vitamins and their effect on mood. In a double-blind 
randomised control trial, 81 healthy young adults experiencing depressive symptoms took 
vitamin C for 14 days. Compared to the placebo group, depression symptoms significantly 
decreased (Jorm & Morgan, 2008). Additionally, a 2009 study found that after six months 
using EMPowerplus, 358 adults with bipolar disorder showed a 45% decrease in symptoms 
(Gately and Kaplan, 2009).  
Finally, a 2010 case study had significant results after using EMPowerplus to treat a 
21 year old female experiencing mood disorders. The woman had experienced bipolar II 
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disorder, ADHD, social anxiety and panic disorder for eight years and was unable to control 
her symptoms with medication. She used EMPowerplus for eight weeks and significantly 
improved her symptoms. After this eight week period she chose to come off the supplement 
and her symptoms reverted back to their original state, with her ADHD symptoms worsening. 
She then chose to go back onto the supplement and her symptoms improved once again. After 
one year on the supplement she was in remission from all of her illnesses (Rucklidge & 
Harrison, 2010).  
There is a necessity for double-blind randomised control trials using micronutrients in 
participants experiencing mood disorders. There is also a need for more exploration beyond 
the use of EMPowerplus. These limitations considered, the results from such studies warrant 
further research into the use of micronutrient supplements as an alternative form of mood 
disorder treatment.  
 
Acceptance toward Alternative Treatments 
There has been a great deal of work in the area of alternative treatments. One researcher in 
the area defines the acceptance of alternative treatments as such:  
The acceptance of alternative treatments refers to the judgments about the treatment 
procedures by non-professions, lay persons, clients, and other potential consumers of 
treatment. Judgments of acceptability are likely to embrace evaluation of whether 
treatment is unfair, reasonable, and intrusive, and whether treatment meets with 
conventional notions about what treatment should be. In general, acceptability refers 
to the overall evaluation of the procedures (Kazdin, 1980). 
It is important to research people’s acceptance toward alternative treatments for several 
reasons. Research is important for the care of the individual seeking treatment. Their opinions 
need to be at the forefront of consideration. If the individual does not accept the alternative 
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treatment there is likely to be low compliance and treatment will not be accurately 
administered. Additionally, it is important is to evaluate legal and ethical acceptance. If the 
treatment infringes on rights of the individual, the treatment will not be accepted by them or 
the general public (Kazdin, 1980). Furthermore, the individual using the alternative treatment 
will be susceptible to the opinions of close family members or friends (known as the 
subjective norm). If family members or friends believe the alternative treatment is not 
worthwhile, there is likelihood that the individual using the treatment will cease doing so 
(Kazdin, French & Sherick, 1981). 
The acceptance of alternative treatments by the general public is important. For some 
mental illnesses, there are several available treatment options. Treatments that are viewed as 
more accepted by the general public are more likely sought out and administered by 
individuals than those that are not (Kazdin, 1980). This demonstrates that it is the view of the 
general public that decides the acceptability of a treatment rather than its efficacy. Other 
factors impacting on acceptance of the public may include the level of success in the past for 
individuals that have used alternative treatments; the ease of administration of new alternative 
treatment and the level of safety when administering the treatment (Kazdin, 1977). 
Additionally, it has been found that females are more likely than males to be accepting 
towards alternative treatments (Kazdin, 1980; Ernst & White, 2000).   
 
Acceptance toward Micronutrient Treatment 
In an Australian survey conducted in 1999, respondents were given a list of pharmacological 
treatments to rate as helpful or harmful. The participants were also given a vignette 
describing the symptoms of depression or schizophrenia. For the depression vignette, 57% of 
respondents rated vitamins, minerals, tonics or herbal medicines as helpful and 3% rated 
them as harmful. Antidepressant medication was rated as helpful by 29% and as harmful by 
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42% of respondents. For the schizophrenia vignette, antidepressants were rated as helpful by 
38%, followed by vitamins and minerals with 34% and antipsychotics with 23% (Jorm, 
Korten, Jacomb, Christensen & Henderson, 1999). The majority of these Australian 
respondents demonstrated that they are accepting of vitamin and mineral treatments for 
depression, which may mean that others are also.  
Certain groups in particular may be more accepting towards the use of micronutrients 
as an alternative treatment for mood disorders than others. 
A study completed in 2002 concluded that people whose lifestyles were healthier 
were more likely to use dietary supplements (Foote, Murphy, Wilkens, Hankin, Henderson & 
Kolonel, 2003). For this reason it would be expected that people who lead healthy lifestyles 
may be more accepting towards micronutrients as an alternative treatment for mood 
disorders, as they may already frequently use them.   
In a review of alternative medical treatment providers (Baer, 2004), it was concluded 
that the drive toward professionalism seen by medical health professionals is a factor that 
limits practitioner provision of CAM. The author states that “professionals have been defined 
by a set of traits including specialised skills and training…limited membership to multiple 
associations, a code of ethics, a service orientation, income by fees rather than wages, 
universalism, and recognition of their authority by the larger society.” The ideal in reaching 
professionalism through limited use of CAM may be a barrier for medical and healthcare 
professionals in the present study to be accepting of micronutrients as an alternative treatment 
for mood disorders.   
There is likelihood that individuals previously experiencing mood disorders will be 
more accepting of micronutrients as an alternative treatment. This may be as a result of 
trialled and rejected previous treatments, leading them to seek out alternative options 
(Kessler, Soukup, Davis, Foster, Wilkey, Van Rompay & Eisenberg, 2001). Research 
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conducted in 2002 concluded that individuals experiencing mood disorders often seek out 
alternative treatments. This is usually as a reflection of limitations in conventional treatments 
as they are not universally effective (Manber, Allen & Morris, 2002). 
Finally, people with lower annual income may be less accepting towards 
micronutrients as an alternative treatment for mood disorders. This may be due to living in an 
environment where health products such as multivitamins are an unnecessary added expense, 
leading to low usage rates and thus rejection. It was reported in studies conducted by the 
United States Centers for Disease Control and Prevention in 2004 and 2005 that ethnic 
minority females with low incomes are amongst the most likely to have lower usage rates of 
multivitamin supplements (Centers for Disease Control and Prevention, 2004; 2005).  
 
Rationale 
With the information presented, it would appear that there is widespread use of micronutrient 
supplements as an alternative form of mood disorder treatment in people attempting to treat 
their own symptoms (Chong, Rajendran & Wint, 2008; Jorm, Christensen, Griffiths & 
Rodgers, 2002). There is also sufficient evidence to suggest that the use of micronutrient 
supplements help to restore nutritional deficiencies in the brain that can be associated with 
mood disorder experience (Kaplan, Crawford, Field & Simpson, 2007; Malouf, Grimley & 
Areosa, 2004; Bottiglieri, Laundy, Crellin, Toone, Carney & Reynolds, 2000; Gariballa & 
Forster, 2007). Additionally, there is evidence that micronutrients have fewer side effects 
than antidepressants or other medications (Dalmiya, et al. 2009). Micronutrients may thus be 
a valuable complementary or alternative treatment option for mood disorders. However, 
treatments that are viewed as more accepted by the general public are more likely to be 
administered by individuals than those that are not (Kazdin, 1980).  
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Acceptance toward micronutrient treatments first needs to be addressed before they 
are able to become more widely used to treat mood disorders. Presently, there is a lack of 
research available focussing on the acceptance towards the use of micronutrient supplements 
as an alternative treatment for mood disorders. This highlights why the current research is 
necessary.  
 
Aim 
Without the acceptance of micronutrients as a mood disorder treatment from mental health 
professionals or consumers of treatments, such valuable treatments may become under-
utilised. The aim of this research is to better understand the acceptance of mental health 
professionals and treatment consumers (among other members of the public) towards 
micronutrients as an alternative treatment for mood disorders. In addition, this research 
wishes to aid individuals experiencing mood disorders to be aware of as many treatment 
options as are available. 
 
Hypotheses 
It is hypothesised that this study will uncover several issues.  
1. It is predicted that females will be more accepting toward micronutrients as alternative 
mood disorder treatment than males. 
2. It is predicted that individuals working as mental health professionals will be less 
accepting of micronutrients as an alternative treatment for mood disorders.  
3. It is predicted that individuals indicating a healthy lifestyle will be more accepting of 
micronutrients as an alternative treatment for mood disorders.  
4. It is predicted that individuals previously experiencing mood disorders will be more 
accepting of micronutrients as an alternative treatment for mood disorders.  
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5. It is predicted that individuals with lower annual income will be less accepting towards 
micronutrients_as_an_alternative_treatment_for_mood_disorders. 
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                                                  Method 
 
Participants 
The final sample consisted of 661 participants (141 male, 520 female), with 244 claiming to 
have experienced a depressive disorder (48 male, 196 female) with a mean age of 34 years 
(SD= 14; range = 18-74); 7 participants claiming to have experienced a bipolar disorder 
(three male, four female) with a mean age of 32 years (SD= 14; range = 20-54); 84 
participants claiming they were unsure if they had experienced a mood disorder (22 male, 62 
female) with a mean age of 30 years (SD= 14; range= 18-78) and 326 participants (67 male, 
259 female) claiming to have never experienced a mood disorder, with a mean age of 34 
years (SD=14; range= 18-80). The majority of participants were residing in New Zealand at 
the time of survey completion (84.2%).  
Initially, participants were recruited by way of advertising on campus of the 
University of Canterbury and suburban Christchurch areas (this advertisement can be found 
in Appendix I); links to the survey were posted on online social networking websites 
including www.facebook.com and www.twitter.com; advertising for the survey was posted 
on the University of Canterbury website on primary research supervisor Dr. Julia Rucklidge’s 
profile page; and participants of previous micronutrient studies conducted at the University of 
Canterbury were notified of the study. Initially these methods combined recruited 
approximately 100 of participants. Links to the survey were then emailed to all undergraduate 
and postgraduate psychology students enrolled in 2011 at the University of Canterbury by the 
psychology administration department, increasing the sample size to approximately 440. This 
caused the sample to skew as the majority were undergraduate psychology students, with 
80% of them female. In an attempt to remedy this, primary research supervisor Julia 
Rucklidge emailed the survey link to colleagues from the New Zealand College of Clinical 
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Psychologists, the American Psychological Association and ‘The Press’ newspaper in 
Christchurch. This increased the sample to a final total of 661 participants with 78.6% female 
and 21.4% male. 
 
Measures 
 Medical Outcomes 36-Item Short-Form Community Health Survey 
Parts of the survey created for the purpose of this study were adapted from the Medical 
Outcomes 36-Item Short Form Community Health Survey Version 1.0 (SF-36). The SF-36 is 
a multi-purpose, short-form generic health survey with functional health and well-being 
scores in the form of Likert scales (Ware & Sherbourne, 1992). 
The reliability of the scale has been estimated using both internal consistency and 
test-retest methods. As reported by Grandek and colleagues in 1998, the SF-36 has good 
internal consistency, and a Cronbach’s Alpha of 0.92, exceeding the minimum standard of 
0.70 recommended for measures (Tsai, Bayliss, & Ware, 1997). The scale additionally has 
adequate discriminatory power and good correlation with other measures (Beaton, Hogg-
Johnson & Bombardier, 1997). A review of the first 15 published studies testing the SF-36 
also revealed that the median reliability coefficients for the SF-36 was equal or greater than 
0.80 (Ware, Snow, Kosinski & Gandek, 1993).  
Validity has been determined as cited in the SF-36 bibliography (Turner-Bowker, 
Bartley, Ware, 2001), by comparison between the SF-36 and 225 other measures. 
 
MacArthur Network on Socio Economic Status and Health Socio-demographic 
Questionnaire 
For questions relating to Socio Economic Status (SES), questions from the The MacArthur 
MICRONUTRIENT TREATMENT IN MOOD DISORDERS 
 
28 
 
Network on Socio Economic Status and Health Socio-demographic Questionnaire were 
adapted (Stuart, 2009).  
The reliability of the questionnaire was tested by Wechsler and colleagues in 1995 
and determined inter-rater reliability of r>.99 and p<.001. Test-retest reliability found a high 
correlation (r=.92 and p<.001) (Wechsler, Basch, Zybert, Lantigua & Shea, 1995). 
Validity of the questionnaire has been determined through comparison with other 
questionnaires (Patterson & Chapman, 2004). 
 
Acceptance toward the use of micronutrients in the treatment of mood disorders 
survey 
The survey created for the purpose of this study was made up of 12 separate sections from 
alternative sources. Details of the sections are outlined as follows: 
Section one (questions 2-6) was demographic in nature, asking the gender, age, 
marital status and ethnicity of the participants. These questions were created by the 
researchers of the present study. 
Section two (questions 7-12) was comprised of SES related questions including 
employment categories, highest qualification, annual income and currency of this income 
(participants who chose not to disclose income amount did not answer question 12). When 
participants were asked about employment category they were asked to input what industry 
they were employed in and what their job title was. These descriptions were then coded into 
one of 30 employment categories as displayed on www.seek.co.nz, a popular international 
employment seeking website. The participant numbers in each group were small and as such 
these 30 categories were later combined to create 13 categories. 
Continuing to cover SES, section three (questions 13-16) asked participants about 
household arrangements, including how many people live in each participant’s household and 
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which people bring income into the household. The questions for sections two and three were 
taken from The MacArthur Network on Socio Economic Status and Health Socio-
demographic Questionnaire (Stuart, 2009).  
Section four (questions 17-21) adapted questions from the SF-36 and related to 
perceived health and its importance. For example, Question 19 listed 10 activities that 
participants may do during a typical day. The participants were then asked to state how much 
their health limits them in these activities. They responded using a three-point Likert Scale 
ranging from ‘Yes, limited a lot’ to ‘No, not limited at all’. Only parts of the SF-36 were used 
to create this survey, comprising of questions from the ‘General Health’ and ‘Physical 
Functioning’ sections.  
Section five (questions 21- 26) asked about possible usage of CAM options 
(participants with no history of alternative treatment usage did not answer question 23). 
Questions included a selection of natural health therapies/products used in the past, how often 
the treatments were used, in what capacity and how often the participant might visit an 
alternative treatment provider. 
Section six (questions 26-30) asked participants about possible diagnosed or 
suspected history with mood disorders. If this answer was confirmed, participants were asked 
to specify which type of mood disorder they experienced. They were then asked if they 
engaged in a ‘conventional’ (defined for the purpose of the survey as any form of 
psychotherapy, counselling, any kind of professional talking therapy and/or any prescribed 
medication) or ‘alternative’ (any non ‘conventional’) treatment for this mood disorder, if any. 
If the participant had no experience with a mood disorder the remainder of this section was 
skipped (questions 27, 28, 29 & 30).  
Section seven (question 31)  was comprised of a five-point Likert Scale asking 
participants how ‘likely’ or ‘unlikely’ they would be to use a selection of treatments if they 
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hypothetically came to be diagnosed (or re-diagnosed) with a mood disorder (ranging from 
‘Very Unlikely’ to ‘Very Likely’). Treatments listed were antidepressants, antipsychotic 
medications, CBT, family therapy, vitamins, minerals and amino acids, group therapy, 
individual therapy, support groups, electroconvulsive therapy, acupuncture, massage therapy, 
yoga, light therapy, magnetic therapy, hypnosis, herbal medicine and breathing exercises. 
This choice of treatments was taken from the 2010 CAM survey of hospitals created by the 
Samueli Institute and the American Hospital Association/Health Forum (Ananth, 2011).  
Sections eight, nine and ten (questions 32-34) assessed participants’ acceptance 
toward the use of micronutrients in the treatment of mood disorders. It was made up of 20 
five-point Likert Scale questions (ranging from ‘Strongly Disagree’ to ‘Strongly Agree’). The 
majority of these statements were taken from the 2010 CAM survey of hospitals created by 
the Samueli Institute and the American Hospital Association/Health Forum (Ananth, 2011). 
The remaining statements (questions 32d, 33g, 34a, 34c and 34f) were created for the purpose 
of this study achieving a satisfactory Chronbachs Alpha of .832.  
Section 11 (questions 35, 36) asked participants if micronutrients and conventional 
treatments were found to be equally effective for treating mood disorders and they came to be 
diagnosed with (or re-diagnosed with) a mood disorder, which treatment would they choose 
first.  
Section 12 (questions 37, 38) asked if micronutrients and conventional treatments 
were found to be equally effective for treating mood disorders and someone the participant 
knew under the age of 18 came to be diagnosed with a mood disorder, how much they would 
agree or disagree with them using micronutrients as a treatment, based on a five-point Likert 
Scale (ranging from ‘I would strongly disagree’ to ‘I would strongly agree’).  
At the completion of these 12 sections participants were free to ask questions or leave 
comments on the subject matter of the survey. 
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The survey in its entirety can be found in Appendix III. 
 
Procedure 
The survey was launched to the public on the Qualtrics Survey Software website on the 31st 
August 2011. It was then removed from Qualtrics on the 24th November 2011. After 
participants had been recruited they were given a link to the Qualtrics Survey Software 
website to complete the survey (http://canterbury.qualtrics.com/SE/?SID=SV_9ntJcZOcPT 
ImnHK). The survey began with an information and consent sheet which participants were 
required to read and agree to before commencing. This information and consent sheet can be 
found in Appendix II. The participants then went on to complete all ten sections of the 
survey. Each section required forced responses for the participants to continue, in order to 
avoid missing data.  
The study was approved by the University of Canterbury Human Ethics Committee 
(UCHEC). Participants were offered entry into a draw of one of two 2Gig 4th Generation iPod 
Shuffles at the completion of the survey as a thank you for their time. The entry into the iPod 
draw was completely separate to the participants’ survey thereby keeping the survey 
anonymous and disassociating any previous responses from entry as per requirement of the 
UCHEC. The study approval confirmation from UCHEC can be found in Appendix IV. 
Upon completion of the survey participants were thanked for their time and supplied 
with contact information for the researchers if they sought debriefing or further information. 
The survey then automatically uploaded their responses before either closing, or opening a 
separate survey for entry into the iPod draw. 
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‘Acceptance’ Score Calculation 
In order to test all hypotheses for this research, overall scores for each participants’ 
‘acceptance’ toward the use of micronutrients as an alternative treatment for mood disorders 
were calculated. Totals were calculated from each question in the attitudes sections of the 
survey (sections eight, nine and ten, questions 31, 32, and 33) in order to determine these 
acceptance scores. Appropriate questions were reverse coded (31b, 31f, 32e, 33c and 33d) 
and each score from these questions was added together for an overall ‘acceptance’ score. 
Each question was scored out of five as the questions were answered using five-point Likert 
Scales. For example, an answer of “strongly disagree” would get a score of one out of five. If 
the participant were to choose “strongly agree” as their answer for the next question, this 
would get them a score of five out of five for that question. These answers would then be 
added together for an overall score of six. This process was carried out for all 20 questions to 
give the participant an overall ‘acceptance’ score out of a possible 100, ranging from 20-100 
(M=69.7). 
 
‘Healthy Lifestyle’ Score Calculation 
Overall ‘healthy lifestyle’ scores were calculated from each question in the health section of 
the survey (section four, questions 16, 17, 18a-j, 19a-d and 20a-d). Appropriate questions 
were reverse coded (16, 17, 19a, 19c, 20b and 20d) and each answer was added together for 
an overall ‘healthy lifestyle’ score. Each question was out of five as the questions were 
answered using five-point Likert Scales. For example, an answer of “strongly disagree” 
would get a score of one out of five. If the participant were to choose “strongly agree” as 
their answer for the next question, this would get them a score of five out of five for that 
question. Question 19 was scored out of three and followed the same process, gaining the 
participant a total possible score of three out of three. This process was carried out for all 20 
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questions to give the participant an overall ‘healthy lifestyle’ score out of a possible 80, 
ranging from 20-80 (M=61.2).  
 
Statistical Analyses 
Data were analysed using ‘STATISTICA’ version 9 and the Statistical Package for Social 
Science version 19.0. T-tests for independent samples were conducted to compare group 
means between gender groups and ‘acceptance’ scores, as well as healthcare and medical 
professionals (including but not limited to psychiatrists, family doctors or general 
practitioners, other medical doctors, psychologists, nurses, social workers, counsellors or 
psychotherapists) against other professional groups and ‘acceptance’ scores. An Analysis of 
Variance (ANOVA) and Tukey honest significant difference post hoc test were conducted to 
compare all professional group means and ‘acceptance’ scores. Pearson product-moment 
correlations were conducted to determine if relationships existed between ‘acceptance’ scores 
and ‘healthy lifestyle’ scores and ‘acceptance’ scores and annual income. A final ANOVA 
was conducted to compare group means between participants and their experiences with 
mood disorders against their ‘acceptance’ scores. 
Following statistical analyses, percentages were calculated for each group based on 
their chosen answer to the question “If micronutrients and conventional treatments were 
found to be equally effective and you came to be diagnosed (or re-diagnosed) with a mood 
disorder what would your first choice of treatment be?” These percentages can be found in 
Appendices V and VI (Tables 5 and 6).  Chi-square statistics were also calculated to 
investigate differences in first treatment choices between males and females, varied 
experiences with mood disorder, and income groups. Averages were also calculated for each 
group for answers out of 5 to the question “If micronutrients and conventional treatments 
were found to be equally effective for treating mood disorders and someone you knew under 
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the age of 18 came to be diagnosed with a mood disorder, would you agree with them using 
micronutrients as a treatment?” (Results of all percentage and average calculations can be 
found in Tables 5 and 6, Appendices V and VI). 
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Results 
 
Preliminary Analysis 
All data were examined for errors and missing items. All efforts were made to avoid these by 
forced response requirements; however, if a participant had omitted or incorrectly filled out 
more items than allowed for any given question, that participant’s answers on that particular 
question were disregarded or corrected where possible. After removal of errors and missing 
items this study had an 86% completion rate with 769 participants beginning the survey and 
661 (141 male, 520 female) completing. 
 Overall it was found that 10.6% (N=70) of participants fell between the ‘disagree’ and 
‘neutral’ range of acceptance (‘acceptance’ score 40-59), 76.7% (N=507) between the 
‘neutral’ and ‘agree’ range of acceptance (‘acceptance’ score 60-79) and 12.7% (N=84) 
between the ‘agree’ and ‘strongly’ agree range of acceptance (‘acceptance’ score 80-100) 
towards the use of micronutrients as an alternative treatment for mood disorders. 
Additionally, if any participants came to be diagnosed or re-diagnosed with a mood disorder, 
and micronutrients were found to be equally effective to conventional treatments, 56.6% said 
that they would choose to use micronutrients first (31.3% chose conventional, 12.1% chose 
other or none). 
 
Exploratory Analyses 
 
Prediction 1: Females will be more accepting to micronutrients as an alternative 
mood disorder treatment than males. 
An independent-samples t-test was conducted to compare ‘acceptance’ scores in male and 
female groups (coded as 1 and 2 respectively). The possible range on the ‘acceptance’ scores 
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was 20-100, where higher scores indicated higher acceptance towards the use of 
micronutrients as a treatment for mood disorders. The obtained range was 42-98.  
There was a marginal effect on ‘acceptance’ scores for females (M=70.00, SD=8.60) 
and males (M=68.55, SD=9.34); t(659)=1.74, p=0.082. Marginal significance suggests that 
the results may have occurred from random chance alone. Marginal significance therefore 
does not give authorisation to suggest significance (Siegel, 1990). These results suggest that 
males and females do not have different ‘acceptance’ scores towards the use of 
micronutrients in the treatment of mood disorders. 
All participants were asked at the conclusion of the survey the following question: “If 
micronutrients and conventional treatments were found to be equally effective for treating 
mood disorders and you came to be diagnosed with (or re-diagnosed with) a mood disorder, 
which treatment would you choose first?” Participants had the choice to answer from the 
following choices: conventional treatment, micronutrient treatment, other treatment or none. 
A Pearson’s Chi Square test was performed to determine if males and females were 
distributed differently across conventional treatment choice (male N=43, female N=164) and 
micronutrient treatment choice (male N=78, female N=296). The test failed to indicate a 
significant difference, X2(1)=3.07, p= 0.92. 
Additionally, gender percentages in response to the question “If micronutrients and 
conventional treatments were found to be equally effective for treating mood disorders and 
you came to be diagnosed with (or re-diagnosed with) a mood disorder, which treatment 
would you choose first?” were calculated and are displayed in Tables 5 and 6 (Appendices V 
and VI).  
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Prediction 2:  Individuals working as healthcare and medical practitioners will 
be less likely to accept micronutrients as an alternative treatment. 
An independent-groups t-test was conducted to compare ‘acceptance’ scores in healthcare 
and medical professional (including but not limited to psychiatrists, family doctors or general 
practitioners, other medical doctors, psychologists, nurses, social workers, counsellors or 
psychotherapists) and non healthcare and medical professional groups (coded as 1 and 0 
respectively). The possible range on the ‘acceptance’ scores was 20-100, where higher scores 
indicated higher acceptance towards the use of micronutrients as a treatment for mood 
disorders. The obtained range was 42-98.  
There was a significant difference in ‘acceptance’ scores for healthcare and medical 
professionals (M=68.30, SD=9.01) and non healthcare and medical professionals (M=70.51, 
SD=8.54); t(659) =3.12, p=0.002. A small effect size was also indicated (Cohen’s d=0.25). 
These results suggest that people in different professions may have different ‘acceptance’ 
scores towards the use of micronutrients in the treatment of mood disorders. Specifically, 
healthcare and medical professionals appear to score lower in ‘acceptance’ scores on average 
when compared with other professions. Mean ‘acceptance’ scores and standard deviations for 
all profession groups are displayed in Table 2.  
Following the t-test a one-way ANOVA was conducted to compare the effect of 
profession overall on ‘acceptance’ scores. The possible range on the ‘acceptance’ scores was 
20-100, where higher scores indicated higher acceptance towards the use of micronutrients as 
a treatment for mood disorders. Professions were coded as detailed in the Method Section, 
displayed in Table 2. This table additionally displays the number in each group, the group 
means and standard deviations. There was a significant effect of profession on ‘acceptance’ 
scores (F(12, 648) = 2.25, p=0.008). Post hoc comparisons using the Tukey honest significant 
difference test were conducted as a result, indicating that the mean for the ‘Self Employment’ 
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group (N=14, M=76.71, SD=10.28, p=0.014) was significantly different than the other 
employment groups. Taken together, these results suggest that self-employment has an effect 
on ‘acceptance’ scores. Specifically, people who are self employed generally score higher in 
acceptance towards the use of micronutrients as a treatment for mood disorders than other 
profession_groups. 
 
Table 2 
Means, Standard Deviations and Number of Participants (N) in Profession Groups for 
‘Acceptance’ Scores 
 
Profession 
 
Code 
 
N= 
 
Mean 
Standard 
Deviation 
Accounting, Banking & Finance 1 8 67.75 5.50 
Administration, Call Centre & Office Support 2 34 72.32 6.18 
Advertising, Marketing & Human Resources 3 6 69.17 14.78 
Construction, Design & Real Estate 4 134 70.09 8.93 
Education, Community Services & Training 5 16 71.50 9.58 
Engineering & Information Technology 6 21 71.19 9.68 
Government, Defence, Conservation & Farming  7 206 67.89 9.01 
Healthcare & Medical 8 107 68.30 9.01 
Hospitality, Tourism, Sports & Recreation 9 18 72.94 7.34 
Manufacturing, Transport, Trades & Services 10 21 71.29 9.62 
Retail & Sales 11 66 69.89 8.35 
Self Employed 12 14 76.71 10.28 
Unemployed 13 10 67.50 9.25 
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Out of interest, mental health professionals were separated from other healthcare and medical 
professionals (including psychiatrists, psychologists, social workers, counsellors or 
psychotherapists) and an independent-groups t-test was conducted to compare ‘acceptance’ 
scores in mental health professionals and non -mental health professional groups. The results 
produced a similar significant difference in group means to that of the healthcare and medical 
professionals against other professionals, with mental health professionals scoring lower on 
average compared with other professions (t(659) =3.58, p=0.0004). Due to the similarity of 
results, mental health professionals remained included in the ‘healthcare and medical 
professionals’ group. 
 
Prediction 3:  Individuals indicating healthy lifestyles will be more accepting 
toward micronutrients. 
The possible range on ‘healthy lifestyle’ scores was 20-80, where higher scores indicated 
higher levels of healthy lifestyle. The obtained range was 35-75. The possible range on the 
‘acceptance’ scores was 20-100, where higher scores indicated higher acceptance towards the 
use of micronutrients as a treatment for mood disorders. The obtained range was 42-98. An 
initial Pearson product-moment correlation coefficient of ‘healthy lifestyle’ scores against 
‘acceptance’ scores revealed that the two groups had a significant small positive relationship 
(r=0.089, n=661, p<0.05). After removal of 3 outliers (participants 271, 318 and 650) this 
correlation increased the significant small positive relationship (r=0.105, n=658, p<0.05). 
This relationship is demonstrated by Figure 1. Overall there was a small positive relationship 
between ‘healthy lifestyle’ scores and ‘acceptance’ scores. Small increases in healthy lifestyle 
were associated with small increases in acceptance of micronutrients as a treatment for mood 
disorders.  
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Figure 1.Association between 'Healthy Lifestyle' Scores and 'Acceptance' Scores 
 
Some notable results occurred in the ‘healthy lifestyle’ and ‘acceptance’ scores. Both males 
and females scored highest in their ‘healthy lifestyle’ score in the 47-60 year old category 
(Tables 5 & 6, Appendices V & IV). Also, ‘healthy lifestyle’ scores for females were on 
average at least 4 points higher in all higher education groups than the ‘less than final year of 
high school’ group, scoring very closely in ‘healthy lifestyle’ scores in all higher educated 
groups. The same result was found in the male group with the ‘less than final year of high 
school’ group scoring on average 8.9 points lower in their ‘healthy lifestyle’ scores than all 
other higher educated groups (Tables 5 & 6, Appendices V & IV). 
 
Prediction 4: Individuals with previous experience with mood disorders will be 
more accepting of micronutrients. 
A one-way ANOVA was conducted to compare the effect of previous experience with a 
mood disorder in ‘Yes’, ‘No’ and ‘Unsure’ groups (coded as 1, 2, and 3 respectively) on 
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‘acceptance’ scores. Means and standard deviations for these groups are presented in Table 3. 
The possible range on the ‘acceptance’ scores was 20-100, where higher scores indicated 
higher acceptance towards the use of micronutrients as a treatment for mood disorders. The 
obtained range was 42-98. There were no statistically significant differences between group 
means (F(2, 658) = 1.46, p=0.23). As such no post-hoc tests were conducted. These results 
suggest that experience with mood disorder does not have an effect on acceptance towards 
the use of micronutrients as a treatment for mood disorders. 
All participants were asked at the conclusion of the survey “If micronutrients and 
conventional treatments were found to be equally effective for treating mood disorders and 
you came to be diagnosed with (or re-diagnosed with) a mood disorder, which treatment 
would you choose first?” Participants had the choice to answer from the following: 
conventional treatment, micronutrient treatment, other treatment or none. A Pearson’s Chi 
Square test was performed to determine if participants with varied experiences with mood 
disorder (yes experience, no experience or unsure) were distributed differently across the 
choice of micronutrient treatment (yes N=129, no N=194, unsure N=51) and conventional 
treatment (yes N=78, no N=108, unsure N=51). The test failed to indicate a significant 
difference across first treatment choices, X2(2)=1.69, p= 0.43. 
 
Table 3 
 Means, Standard Deviations and Number of Participants (N) in ‘Experience with Mood 
Disorder’ Groups for ‘Acceptance’ Scores 
Experience with 
Mood Disorder 
Group 
 
N= 
 
Mean 
 
Standard 
Deviation 
Yes 251 69.53 8.65 
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No 326 69.42 9.01 
Unsure 84 71.21 7.16 
 
 
Prediction 5: Individuals with lower annual household income will be less 
accepting toward micronutrients as an alternative treatment. 
The possible range on annual income was $0-$100,000 or more. The obtained range was $0-
$100,000 or more. The possible range on ‘acceptance’ scores was 20-100, where higher 
scores indicated higher acceptance towards the use of micronutrients as a treatment for mood 
disorders. The obtained range was 42-98. A Pearson product-moment correlation coefficient 
of ‘annual income’ against ‘acceptance’ scores revealed that the two groups had an 
insignificant negative relationship (r=-0.066, n=613, p<0.05) (‘Don’t Know’ and ‘Unsure’ 
income groups were removed from the analysis). Means and standard deviations of all 
income groups are displayed in Table 4. These results suggest that lower annual household 
income does not have an effect on acceptance towards the use of micronutrients as a 
treatment for mood disorders. 
All participants were asked at the conclusion of the survey “If micronutrients and 
conventional treatments were found to be equally effective for treating mood disorders and 
you came to be diagnosed with (or re-diagnosed with) a mood disorder, which treatment 
would you choose first?” Participants had the choice to answer from the following: 
conventional treatment, micronutrient treatment, other treatment or none. Income groups 
were separated into ‘low’ (less than $5,000-$15,999), ‘medium’ ($16,000-$49,999) and 
‘high’ ($50,000- more than $100,000). A Pearson’s Chi Square test was performed to 
determine if participants with ‘low’, ‘medium’ or ‘high’ incomes were distributed differently 
across the choice of micronutrient treatment (low N=132, medium N=114, high N=105) and 
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conventional treatment (low N=82, medium N=45, high N=65). The test failed to indicate a 
significant difference across first treatment choices, X2(2)=4.9, p= 0.09. 
 
Table 4 
Means, Standard Deviations and Number of Participants (N) in Income Groups for 
‘Acceptance’ Scores 
Income Group 
($NZD) 
Code N= Mean Standard 
Deviation 
Less than 5,000 1 93 69.57 7.98 
5,000-11,999 2 104 70.13 8.54 
12,000-15,999 3 37 72.00 10.63 
16,000-24,999 4 72 69.50 8.76 
25,000-34,999 5 44 71.25 8.59 
35,000-49,999 6 66 70.97 9.14 
50,000-74,999 7 103 69.48 8.06 
75,000-99,000 8 57 67.40 7.32 
100,000 or greater 9 37 68.70 12.47 
 
 
Adolescents 
No predictions were created involving the acceptance towards the use of micronutrients to 
treat mood disorders in people under the age of 18. However, as data was collected asking 
participants to rate on a Likert Scale from 1 (strongly disagree) to 5 (strongly agree) about 
their feelings towards the matter, a statistical analysis was carried out. 
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The possible range on the overall ‘acceptance’ scores was 20-100, where higher 
scores indicated higher acceptance towards the use of micronutrients as a treatment for mood 
disorders. The obtained range was 42-98. Although in the ‘acceptance’ scores sections of the 
survey there were no specifications in the statements about the person using micronutrients 
being over or under 18, overall ‘acceptance’ scores were based on the personal point of view 
of the participant taking the survey. Participants under the age of 18 were excluded from the 
survey, as such there were no overlapping overall ‘acceptance’ scores with acceptance 
‘towards the use of micronutrient treatment in people under the age of 18’ scores. The 
possible range on acceptance ‘towards the use of micronutrient treatment in people under the 
age of 18’ score was 1-5, where a higher score indicated higher acceptance towards the use of 
micronutrients as a treatment for mood disorders in people under the age of 18. The obtained 
range was 1-5. A Pearson product-moment correlation coefficient of ‘acceptance’ scores 
against acceptance ‘towards people under the age of 18’ scores revealed that the two groups 
had a significant positive relationship (r=0.407, n=661, p < 0.05). After removal of 1 outlier 
(participant 286) this correlation increased the significant positive relationship (r=0.411, 
n=660, p < 0.05). Overall there was a positive relationship between ‘acceptance’ scores and 
acceptance ‘towards people under the age of 18’ scores. Increases in overall acceptance were 
associated with increases in acceptance of micronutrients as a treatment for mood disorders 
for people under the age of 18. 
MICRONUTRIENT TREATMENT IN MOOD DISORDERS 
 
45 
 
Discussion 
 
Purpose of Research 
The aim of the present research was to better understand the acceptance of mental health 
professionals and consumers of treatment (among other members of the public) towards 
micronutrients as a treatment for mood disorders. Without the acceptance of micronutrients 
as a mood disorder treatment from mental health professionals or consumers of treatments, 
such valuable treatments may become under-utilised. In addition, this research wished to aid 
individuals experiencing mood disorders to be aware of as many treatment options as are 
available. 
Overall, it was found that most participants fell between the ‘neutral’ and ‘agree’ 
range of acceptance for micronutrients as an alternative treatment for mood disorders. 
Additionally, over half of participants said that they would choose to use micronutrients first 
over conventional or other treatments should they came to be diagnosed or re-diagnosed with 
a mood disorder. 
 
Gender Differences 
It was initially predicted that females would be more accepting toward micronutrients as 
alternative mood disorder treatment than men. This prediction was due to reports that females 
are more likely to accept alternative treatments than men (Kazdin, 1980). Additionally, in a 
study conducted by the American National Centre for Health Statistics’ and the ‘American 
National Centre for Complementary and Alternative Medicines’, women were found to be 
more likely to use complementary and alternative medicines than men (Barnes, Powell-
Griner, McFann & Nahin, 2004). The hypothesis was tested and found to be insignificant.
 Participants were asked at the completion of the survey what their first choice of 
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treatment would be should they come to be diagnosed (or re-diagnosed) with a mood disorder 
if conventional treatments and micronutrient treatments were found to be equally effective. In 
the analysis of these answers there were also no differences indicated between males and 
females. 
The results found may be due to multiple factors. There was an overwhelming ratio of 
females to males in this study (78% to 22% respectively), with females being considerably 
overrepresented compared to males. There may additionally be particular motives behind the 
ways that males and females use and accept alternative treatments such as micronutrients 
when treating a mood disorder which deserve some consideration.  
There has been little work done on motives behind alternative treatment choices in 
males and females. A study conducted in 2005 investigated the motives behind use of CAM 
(specifically dietary supplements) amongst male and female cancer patients. A telephone 
survey found that 81.5% of female participants had used some form of CAM versus 59.9% of 
males. It was concluded that female usage of CAM was more common in those seeking 
additional dietary supplements; seeking focused mental therapies and lifestyle changes. CAM 
usage among males was common in those seeking help with cancer symptom related distress, 
and dissatisfaction with conventional treatment providers. Surprisingly, motives for CAM 
usage for females decreased with dissatisfaction with conventional treatment providers and 
cancer symptom related distress (Hendderson, Patterson, Neuhouser, Schwartz, Bowen, 
Standish & Marshall, 2005). The overarching conclusions of this study were that there is an 
important difference in the way that males and females use CAM. This may be due to 
physiological differences between the two and result in the higher ratio of females using such 
treatments. Perhaps in the present study there were no group differences in gender as it may 
be common for females to use CAM more frequently than men but not in the current context. 
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Females may use CAM in the form of dietary supplements for potentially fatal illnesses such 
as cancer but not in the event of mental health illnesses such as mood disorders. 
McLaughlin and colleagues (2011) found that in older age populations it is men who 
more commonly use CAM than women. Men were found to be 1.79 times more likely to use 
CAM between the ages of 77 and 91. These results may imply that in younger populations, 
females would more commonly use CAM. The present study had a wide age range of 
participants (18-74) but as results were not significant, higher acceptance was not found 
between female or male participants regardless of age. The study additionally concluded that 
both men and women were using CAM to maintain good health for treatment of ongoing 
ailments. As there were only slight differences between men and women in the present study, 
perhaps males and females using alternative treatments are using them for similar reasons. 
The non-significant gender differences in this study may conflict with previous 
research as the mentioned studies looked at the gender rates of use of CAM and the motives 
behind the usage. This study focussed on participant’s acceptance of usage of alternative 
treatments (specifically micronutrients) and was not focussed around how often or the 
reasoning behind why participants typically use CAM. Past studies record females as having 
a higher usage of CAM but there appears to be little research around acceptance of their use 
(with the exception of the work done by Kazdin in 1980). Females may report high use of 
alternative treatments but not necessarily agree with their use.  
The studies discussed largely make conclusions from their research with the use of the 
phrase ‘complementary and/or alternative medicine’ (CAM). Participants (male and female) 
in the current study may not have associated the term ‘micronutrients’ with the phrase CAM 
as seen in the past. This may have altered participants’ ‘acceptance’ towards such treatments 
as it was presented to them in a different form. Upchurch and Chyu found in 2005 that 
women were more accepting of prayer, relaxation and exercise forms of CAM (Upchurch & 
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Chyu, 2005). As these forms of alternative treatment under the CAM title have been accepted 
in past research but were not included in the present study (as well as the phrase ‘CAM’ 
itself), females may have been less accepting of micronutrients as an alternative treatment as 
they were less familiar. 
As discussed in the introduction, females exceed males in New Zealand for their 
prevalence of major depressive disorder by 8.9% (Oakley-Brown et al. 2006). Perhaps as 
found by previous research (Yates et al., 2005; Hendderson, 2005) females are indeed more 
likely to use CAM. However females are also more likely than males to experience mood 
disorders. This increased mood disorder rate by females was not large in the present study. 
As indicated in Table 13 (Appendix V), males were only 1.4% lower than females in 
previous experience with mood disorder. This difference, although small, may offer another 
suggestion as to why the current study has not matched previous research concluding that 
females are more likely to use alternative treatments – perhaps the females in this study were 
not experiencing the same need for treatment over males as in previous research.  
 Finally, the introduction included that the onset of mood disorders in females is 
common for those who have recently given birth. Prevalence of postnatal depression in New 
Zealand is particularly high compared to the rest of the world with only 13% of women 
seeking help with treatment (Thio, 2006). An alternative treatment such as micronutrients that 
provide a form of self-medication without the need of others may be particularly beneficial 
for these women. Without data given on females experience with childbirth, it is difficult to 
know how many females in the study have experienced postpartum depression specifically. 
One participant however, was hopeful about the use of micronutrients in the treatment of 
postpartum depression stating “…I hope to see more research on the use of micronutrients for 
the treatment of depression. This would provide some women who have postpartum 
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depression and want to continue breastfeeding with better treatment options that would not be 
harmful to the baby.” 
 
Healthcare and Medical Practitioners 
It was predicted that individuals working in healthcare and medical professions would be less 
likely to accept micronutrients as an alternative treatment for mood disorders. A 2004 review 
concluded that the drive toward professionalism seen by medical health professionals is a 
factor that limits practitioner provision of CAM (Baer, 2004).  
  Statistical analyses of healthcare and medical professionals against other professionals 
resulted in a significant difference between healthcare and medical professionals in their 
acceptance towards the use of micronutrients compared to other professional groups. 
Specifically, healthcare and medical professionals scored lower ‘acceptance’ scores on 
average when compared to other professionals. Additionally, individuals that were 
categorised as ‘self-employed’ had significantly higher ‘acceptance’ scores compared to other 
professional groups. This ‘self-employment’ finding may have been due to the low group 
number and high standard deviation (displayed in Table 2), or the possibility that a variety of 
professional categories were represented by this single group.  
Healthcare and medical practitioners may be affected in their acceptance towards 
micronutrients as an alternative treatment based on their patients’ wishes. A study in 2006 
concluded that likelihood of referral to CAM specialists from GPs was based on two 
overarching factors, one being the patients’ attitudes towards CAM and the other being the 
GPs attitudes and relationships they themselves had towards CAM practitioners (Brien, 
Howells, Leydon & Lewith, 2006).  An additional study concluding that the patient interest is 
highly important in the GPs use of CAM was conducted in 2003. This found that GPs were 
more inclined to refer patients to CAM provided that they displayed interest in such 
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treatments (Thomas, Coleman & Nicholl, 2003). These studies suggest that healthcare and 
medical practitioner acceptance is highly dependent on patient acceptance. Furthermore, the 
same study also found that just under half of the patients viewed three of 13 CAM treatments 
studied as conventional. Individuals (patients or healthcare and medical professionals) may 
not decide to use CAM treatments as their first option of treatment but may in fact view some 
CAM treatments as conventional. The current research however tested specifically for 
micronutrients as an alternative treatment for mood disorders and not CAM in its entirety. 
Perhaps in this instance healthcare and medical professionals are accepting of CAM 
treatments (as was found in Poynton, Dowell, Dew and Egan, 2006 with 94.7% of 
practitioner respondents referring patients to CAM therapies) but not micronutrients 
specifically. 
 A reoccurring theme in research based on healthcare and medical practitioner 
attitudes towards CAM is the need for increased education around alternative treatments.  A 
Kentucky based study concluded that medical practitioners would be more motivated to use 
CAM to appropriately advise patients if they were provided with clinically relevant education 
(Flannery, Love, Pearce, Luan & Elder, 2006). A study conducted in 1988 concluded that 
54% of Wellington GPs expressed an interest in training in CAM therapies (Hadley, 1988). 
Aditionally, it was found in 1998 that the best predictors of United States primary care 
physicians’ use of CAM were attitude of physicians towards CAM and their training around 
usage (Berman, Singh, Hartnoll, Singh & Reilly, 1998). These conclusions were reflected in a 
2001 questionnaire that 32% of GP respondents either personally or within their clinical team 
were involved with CAM treatments despite the fact that only 5.2% of GPs had had some 
form of CAM training in one or more CAM therapies (Lewith, Hyland & Gray, 2001).   
 Additional themes in research on healthcare practitioner use or referral of CAM 
treatments were patient request (distinguishable from patient interest); CAM practitioners not 
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being available at their practice or institution therefore having nowhere nearby to refer 
patients; failure from conventional treatments; patient cultural needs that are not able to be 
met by conventional treatments and/or positive prior experiences with CAM (Poynton et al. 
2006). This reasoning may provide further explanation to results in the current research. It is 
possible that some of the healthcare and medical practitioners surveyed have used CAM 
treatments in the past and these have failed where conventional treatments have succeeded.  
 There is a wealth of research focussed on GPs attitudes towards CAM based in 
European and North American countries. In a study conducted by Japanese researchers in 
1999, it was found that CAM treatments were practised by 73% of the medical practitioners 
surveyed. Chinese herbal medicine Kampo has become part of Japanese mainstream 
medicine over the last 100 years and as such 25% of practitioners considered Kampo not as a 
complementary medicine but a conventional treatment. This attitude of Japanese doctors to 
CAM may reflect the local history and beliefs around treatment (Imanishi, Watanabe, Satoh 
& Ozasa, 1999). The current research may have resulted in local beliefs and culture based on 
the sample, 93% of which was made up of New Zealand European, other European and North 
American participants (Tables 13 & 14, Appendices V & IV). As such, healthcare and 
medical professional acceptance towards micronutrients as an alternative treatment for mood 
disorders may not reflect non-Western culture and may vary in more diverse samples. 
 In a later Japanese study (Teramoto, 2000) it was found that GPs attitudes towards 
CAM are different between university and private hospitals. In the 1999 survey 76% of 
doctors in a Tokyo University hospital regarded Kampo as a complementary medicine. 
However, in a Tokyo private hospital in the same year 57% of doctors recognised Kampo as 
a conventional medicine. Acceptance towards alternative treatment may come from the 
practice at which the healthcare and/or medical professionals work, varying based on if the 
practitioner works in a private practice, hospital or otherwise. This result may occur due to 
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different staff values or collective training. The differences concluded in the Tokyo hospitals 
study may also have come from alternative training between the two groups. The two 
hospitals may train doctors to use CAM treatments in different ways, or vary in their clinical 
training. This idea may be displayed current study. Different levels of training between 
healthcare and medical practitioners in their acceptance towards micronutrients may have 
produced lower ‘acceptance’ scores than in other research. 
 A valid argument as to why healthcare and medical professionals in the current study 
are not as accepting as other professional groups is simply that society expects them to 
provide evidence based treatments, and this is what they have been trained to provide. 
However New Zealand Medical Council guidelines recommend that GPs are aware of CAM 
treatments even if they do not intend on using them, as they play an important role alongside 
conventional treatments in providing quality care (Medical Council of New Zealand, 2005).   
 The overarching theme in studies conducted based on practitioner use and attitudes 
toward CAM is lack of scientific evidence for these therapies. Poynton and colleagues in 
2006 found that 88% of GPs surveyed did not wish to refer patients to CAM therapies based 
on lack of clinical evidence. These results came alongside the statistic that the total number of 
GPs practising CAM treatments has decreased from 30% in 1999 to 20.3% in 2006. It was 
also found that GPs felt CAM should be subject to more scientific testing and that it is less 
powerful than conventional medicine. The physicians in the study were concerned about the 
safety of CAM and the diagnostic ability of CAM therapists (Lewith, Hyland & Gray, 2001). 
Perhaps in order for healthcare and medical professionals in the current study to be more 
accepting toward the use of micronutrients as a treatment for mood disorders more research 
needs to be conducted which provide evidence of clinical effectiveness. 
The comment section at the conclusion of the survey gave some insight into feelings 
of a healthcare and medical practitioner and the use of micronutrient treatment: “I would be 
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interested in any research on effectiveness or effects of micronutrients on mood disorders and 
would likely recommend them in my practice if I knew more.” Two healthcare and medical 
practitioners had this to say about the use of conventional treatments: “I am a clinical 
psychologist, trained in providing evidence-based psychotherapies, and I believe in the 
effectiveness of these treatments.” “It's my profession, I strongly believe in the efficacy of 
CBT, and I know more about it.” 
 
Healthy Lifestyles 
It was predicted that individuals indicating health as important to their lives would be more 
accepting of micronutrients as an alternative treatment for mood disorders. A study 
completed in 2002 concluded that people whose lifestyles were healthier were more likely to 
use dietary supplements (Foote et al. 2003).  
Statistical analysis resulted in calculated ‘healthy lifestyle’ scores having a significant 
small positive relationship with calculated ‘acceptance’ scores. This association demonstrated 
that participants who felt that health was an important aspect of their lives would be more 
likely to be more accepting of micronutrients as a treatment for mood disorders. As with any 
correlational design the direction of the relationship can never be assumed and correlation 
alone does not mean healthy lifestyle causes acceptance of micronutrients. Although the 
effect size was small (0.25), it is important to investigate why this result may have occurred. 
Although there is limited research behind motives in consumption of vitamins, 
supplements or micronutrients, one important study conducted in 2003 found multiple factors 
associated with supplement use. The study concluded that people whose lifestyles were 
healthier were more likely to use dietary supplements (Foote et al. 2003). 
A sample of African-American, Native Hawaiian, Latino, Japanese-American and 
Caucasian American adults completed a questionnaire based on supplement use. 
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Multivitamins were the most frequently reported supplement with 56% of females and 48% 
of males reporting regular use. Multivitamin use was associated with older age. This may be 
due to such participants having a greater number of years than other groups to become 
educated in nutrition and vitamin use. Additionally, older age groups may also tend to use 
micronutrients more than other groups as it has been a habit longer for them and thus they 
would be more likely to continue with this habit (Foote et al. 2003). 
Foote and colleagues also found in 2003 that multivitamin use was associated with 
education. The current research foundsimilar results, with all ‘healthy lifestyle’ scores being 
higher on average in all education groups above the ‘less than final year of high school’ 
group. Furthermore, the lowest educated group scored lower on average for ‘healthy lifestyle’ 
scores than all other higher educated groups.  
In line with the current prediction, it was found that dietary supplement use tends to 
increase with physical activity, fruit intake and a diet high in fibre (Foote et al. 2003). These 
findings would support the idea that people who have more interest in maintaining a healthy 
lifestyle are more likely to take multivitamins and as suggested in the present study, be more 
likely to accept them as an alternative treatment for mood disorders. In this same study, the 
researchers also found that participants who were obese, smokers, and had a high fat diet 
were less inclined to use dietary supplements. Interestingly, it was also found that participants 
who were former smokers were frequent users of supplements at the time of study (Foote et 
al. 2003).  
The dietary supplement market is rapidly growing worldwide (Lee, 2003). This 
finding may impact the current research. People may become more accepting to 
micronutrients as an alternative treatment for mood disorders as years progress and the 
supplement market grows. People will become heavily confronted with these products. This 
suggestion aligns with an additional finding that people are becoming more aware of studies 
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done involving multivitamins and other dietary supplements (Foote et al. 2003). These 
studies reinforce the knowledge base that specific dietary nutrients lower disease, thus 
affecting the attitudes of the public. Perhaps the more studies that are done displaying the 
benefits of using such multivitamin or supplement treatments, the more people will become 
more accepting towards them as an alternative treatment for mental as well as physical 
illness. 
It is important to investigate the quantity of supplements used by individuals who 
regard leading a healthy life as important to them. Foote and colleagues found in 2003 that 
supplement use was more common in healthy people who use multiple nutrients. Participants 
were looking to use one supplement housing many nutrients to provide for multiple dietary 
recommendations. This may suggest that if participants in the current study were asked about 
their acceptance towards particular vitamins (B or C for example) in the treatment of mood 
disorders, they may not have scored as highly as they may be more accepting of the use of 
vitamins in combination. Their findings however do not lead to the result that all “health 
conscious” people (the label given by the researchers to participants that lead healthy lives 
and use supplements) use multivitamins or other supplements. Demographic and lifestyle 
factors used in the 2003 study did not explain all of the differences in users and non-users. 
The high prevalence of dietary supplement use across people who lead healthy lifestyles 
however was significant.  
A 2007 survey collected data regarding motives and practice in athlete supplement 
use for maintenance of health (Petroczi, Naughton, Mazanov, Holloway & Bingham, 2007). 
Adolescent athletes reported use of supplement use for perceived short-term health benefits; 
preventing illness; increased sports performance; maintenance of healthy diet and improving 
immunity. The study concluded that motivation for use and usage of particular supplements 
demonstrated incongruent reasoning. This may indicate that people, or in this case 
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adolescents, who lead healthy lifestyles and are regular users of supplements or multivitamins 
may not necessarily have enough education about their effects. This may have implications 
for the current study. Participants indicating ‘healthy lifestyles’ may be more accepting of 
micronutrients as an alternative treatment, but not necessarily understand their functioning. It 
was a common occurrence in the comment section at the conclusion of the survey for 
participants to claim that they may have been more accepting of micronutrients if they knew 
more about them. Petroczi and colleagues (2007) demonstrated that healthy people may 
employ supplements as a treatment regardless.  One participant reflected:  
I'd be interested in seeing more scientific research on the effects of micronutrients on 
mood disorders. Much of my knowledge comes from health/fitness/diet magazines, 
which tend to overwhelm the reader with recommendations for dealing with problems 
and seem to gather their evidence for such recommendations from various reliable and 
unreliable sources. This is perhaps why I have less faith in micronutrients for treating 
psychological conditions, though I absolutely recognise the importance of  good 
physical health to good mental health; maybe the 'misapplication' of micronutrients 
should be regulated.  
 
Mood Disorder Experience 
It was predicted that individuals with previous experience with mood disorders would be 
more accepting of micronutrients as an alternative treatment for their disorder than 
individuals without experience with a mood disorder. This was predicted due to possible 
rejection of previous treatments (Kessler et al. 2003; Manber et al. 2002).   
Statistical analyses indicated insignificant differences between the experience with 
mood disorder group and the no experience with mood disorder group. The results suggest 
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that experience with mood disorder does not have an effect on acceptance towards the use of 
micronutrients as a treatment for mood disorders. 
A study conducted in 2001 found results similar to those hypothesised. Kessler and 
others surveyed 2055 respondents based on treatments used for various health conditions. It 
was concluded that CAM therapies were used more than conventional therapies by people 
with depression. Although these results were not replicated by the current study, surprisingly 
amongst the ‘experience with mood disorder’ groups, the ‘unsure’ group on average scored 
higher in their acceptance towards alternative micronutrient treatments than the ‘yes’ or ‘no’ 
groups. People who are unsure of their experience with mood disorders may be more open to 
alternative treatments for them. Perhaps without professional diagnosis there will have been 
no corresponding conventional treatment prescribed, thus the ‘unsure’ group may have had 
no experience with conventional treatments. Additionally, without diagnoses, these 
individuals may have self-medicated through the use of easily accessed treatments such as 
multivitamins. Poynton and colleagues (2006) found that sales of St. Johns Wort increased by 
2800% in the United States between 1997 and 1998 for the self-treatment of mild depression. 
It was found by Kessler and colleagues (2001) that the majority of participants 
visiting conventional mental health providers were additionally using alternative treatments. 
This phenomenon was demonstrated in the current study (Question 36) where participants 
were asked to explain why they chose particular treatments as their first choice should they 
come to be diagnosed or re-diagnosed with a mood disorder. Many participants chose 
conventional treatments or micronutrient treatments but said they would not use one 
treatment without the other. The most common combination treatment choice came in the 
form of CBT coupled with micronutrients. This was demonstrated in the following comment: 
I would be hesitant to recommend or use micronutrients as the sole treatment for any 
mood disorder, because I think just giving pills to a patient is unethical when CBT is 
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also a possibility. I think the mood disorder is more likely to relapse without CBT 
unless the patient/I took the micronutrient formula for the rest of his/her/my life, and 
I wouldn't want to have to take pills that long when there is an alternative (CBT). 
However, since they are likely to have fewer side effects than 
antidepressants/psychotics, I would use/recommend micronutrients as a 
complementary therapy to CBT without reservation, when I would only recommend 
antidepressants/psychotics as complementary therapy under extreme circumstances. 
 
A survey of 1035 participants was conducted to test the hypothesis that people turn to 
alternative treatment as a result of being dissatisfied with conventional treatment. The results 
of the survey concluded that dissatisfaction with conventional medicine did not predict 
alternative health care use (Astin, 1998). The survey also found that people who turn to 
alternative treatment are more highly educated. It was uncovered that forms of CAM such as 
relaxation, exercise, and herbs were the most common forms for people experiencing 
depression. This may offer a suggestion as to why participants experiencing mood disorders 
in the present study were not more accepting than others of the use of micronutrients. The 
1998 study concluded that people using alternative treatments are not doing so because they 
are dissatisfied with conventional treatments but find these treatments more in line with their 
values, beliefs and philosophies. Participants in the present study who have experience mood 
disorders may not be typical users of multivitamins based on their values or philosophies and 
thus may be less likely to accept them as an alternative treatment.  
A Canadian study looked at the help-seeking behaviours of people experiencing mood 
disorders. It was found that 1.6% of 1956 individuals experiencing mood disorders used 
vitamins for mental health problems. These were the most highly used natural health products 
for mental health problems (Wang, Patten, Williams, Currie, Beck, Maxwell & El-Guebaly, 
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2005). These individuals may use vitamins in higher numbers but this may be for other 
purposes. Additionally 49% of participants in the sample used conventional treatments and 
the remaining used other or no forms of treatment. This sample demonstrates that 
conventional treatment is used more often than alternative treatments in people experiencing 
mood disorders. It may also suggest that people are open to the use of supplements dependent 
on their purpose.   
As mentioned with gender differences, an additional reason as to why the current 
hypothesis may have been unconfirmed is that people with mood disorders may not 
necessarily ‘accept’ the use of micronutrients as a treatment for mood disorders but this may 
not mean that they would not use them at all. In the current study 56.6% of participants chose 
micronutrients as their first choice of treatment should they come to be diagnosed or re-
diagnosed with a mood disorder, with 31.3% first choosing conventional treatment (the 
remainder choosing other or no treatment).  
It was concluded in a study by Deng and Cassileth in 2006 that for patients with long-
standing symptoms and diagnoses of general anxiety or major depression, pharmacological 
treatments are effective. However, CAM may reduce the amount of medication needed. They 
may also be seen as a welcome option after a lengthy experience with the disorder. Although 
not consistent with the results of the current prediction, this was demonstrated by one 
participant in the present study: “Antidepressants are something that I can see myself on 
forever, I hate that feeling. I would have loved to have had the option to try something 
different when originally diagnosed with depression.”  
It was concluded in 2006 that mood disorders may present themselves as a result of 
another health issue such as a cancer diagnosis. Such diagnoses have potential to alter the 
view of alternative treatments, as chemotherapy or other conventional treatments are rejected 
or inappropriate (Deng & Cassileth, 2006). Participants experiencing mood disorders in the 
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present study may not have experienced life-threatening diagnoses previously, and therefore 
vary in their levels of acceptance to those who have. However without data from participants 
displaying previous health ailments, this is impossible to deduce.  
 
Household Annual Income 
It was finally predicted that people with lower annual household income would be less 
accepting towards micronutrients as an alternative treatment for mood disorders. This was 
predicted due to lower income individuals potentially living in a situation where health 
products such as multivitamins are viewed as an unnecessary added expense, leading to non-
use (Centers for Disease Control and Prevention, 2004; 2005). Insignificant statistical 
analyses suggest that lower annual household income does not have an effect on acceptance 
towards the use of micronutrients as a treatment for mood disorders. 
In a North American study on females by Manber, Allen and Morris (2002) the cost 
breakdowns and efficacy of alternative treatments commonly used to treat depression were 
evaluated. Exercise, stress reduction methods, bright light exposure, herbal treatments (such 
as St. Johns Wort) and acupuncture were all evaluated as being relatively cheap or (in the 
case of acupuncture) covered by insurance companies and highly effective in treating various 
depressive disorders. This study demonstrates that alternative treatments for mood disorders 
in fact are relatively accessible to most income brackets. Although 
multivitamins/micronutrients were not assessed in the study, it may be gathered that if people 
know such treatments are available for treating depression, are easily accessed and relatively 
low in cost, this may be reason enough for low income bracket earners to be equally 
accepting toward them as a treatment for mood disorders as other income groups. 
 It has been reported that vitamins are an inexpensive way to gain vital nutrients for 
the human body. A study by Johnson, Bernard and Funderburg in 2002 concluded that the 
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low cost of multivitamins are more worthwhile and effective than individual vitamins unless 
a deficiency is present. Additionally Fletcher and Fairfield reported in 2002 that the cost of 
name-brand multivitamins may be as small as 20 dollars to 30 dollars monthly or generic 
vitamins around a low 10 dollars. Individual vitamins can be bought at an even lower cost 
which may benefit childbearing women in need of folate for example. At this low cost the 
authors recommend that all adults take at least one multivitamin a day to ensure maintenance 
of essential nutrients, however a higher dosage of nutrients than those offered by generic 
vitamins would be most effective. 
It would appear that multivitamins benefit the human body and come at an affordable 
price, demonstrating positive reasoning for why lower income participants in the current 
study were not less accepting towards them as a treatment for mood disorders than other 
income groups.  
 Finally, a possibility for the unconfirmed hypothesis may be based on the sample. The 
most accepting income group was categorised as ‘low’ ($12,000-$15,999) as displayed in 
Table 5 & 6 (Appendices V and VI). This income brackets is also regarded as low by the 
Ministry of Social Development (Ministry of Social Development, 2010). Although there was 
no statistical significance found, it is notable that highest acceptance was scored by low 
earning participants. It is likely that this has occurred based on the large number of 
undergraduate students recruited for the study. The undergraduate students in this sample 
largely studied psychology. Perhaps the unconfirmed hypothesis has occurred because these 
students would be low income earners and most likely be engaged with the study of mental 
health on more of a day-to-day basis and perhaps more accepting to alternative treatments for 
mood disorders. No conclusions can be drawn from this result however as the hypothesis was 
not confirmed. Overall the sample was not representative of all income groups and was 
therefore a likely reason for the unconfirmed hypothesis.  
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Adolescents 
Although not a listed prediction, the study asked participants a question about their feelings 
towards the use of micronutrients to treat a mood disorder for people under the age of 18. The 
results of such data were also requested by participants in the study. Increases in overall 
acceptance were associated with increases in acceptance of micronutrients as a treatment for 
mood disorders for people under the age of 18. Following this question, the survey had a 
comment section asking participants why they accepted micronutrients for under 18 year-olds 
as strongly or as weakly as they did.  
 It seems a natural outcome that the more accepting a person would be towards the use 
of micronutrients the more accepting they would be to see a person under the age of 18 use 
the same treatment. As discussed in the introduction, young people are at a high risk for 
mood disorders, being one of the most experienced mental disorders by people up to the age 
of 18 in New Zealand (Fergusson et al. 1997). With such high rates of mood disorders in 
New Zealand it is important than any treatment plan for this under 18 age group is well 
supervised. Petroczi and colleagues (2007) investigated motives and practice amongst 
adolescent athletes in their supplement use for maintenance of health. These nutritional 
supplements were usually provided to them by their parents or caregivers and consumed 
without being aware of potential health risks; this reiterates the need for supervision with the 
use of micronutrients when treating mood disorders in individuals under the age of 18. 
Similar sentiments were shared by a participant: “It is best to try something natural first under 
strict supervision.” This is especially important as it was found in one study (Klein, McNulty 
& Flatau, 1998) that 8% of adolescents had seen a health care provider without their parents’ 
knowledge. 
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 A survey conducted by Wilson and Klein in 2002 questioning 361 adolescents about 
their experiences with CAM found that 10.6% of the sample had used vitamins as a CAM 
treatment in the last six months, 55.7% of whom had disclosed this information to their GP. 
The remaining participants may have been afraid that their caregivers may find out, with 
56.1% of participants saying that their parents do not use CAM. For such reasons it is 
important that adolescents are given as many options as possible when looking at treatments 
for treating their mood disorders and that they are fully supported by their caregivers and 
health practitioners in the decisions that they make – be that to employ conventional 
treatment, alternative treatment, a combination, or no treatment.  
 In the comment section of the adolescent question in the survey, there were many 
comments in favour of the individual under 18 being able to make the decision for 
themselves as to what treatment they choose. One comment from someone who had treated 
depression in the past: “I had awful experiences being on anti-depressants as a teenager, so 
many side effects! Made me feel like a zombie. I think you need to make your body healthy 
as a part of becoming well again, especially without the terrible side effects.” Another 
participant was in favour of whichever treatment works best for the adolescent: “I feel 
strongly against taking antidepressants for myself but have no opinion on what other people 
should take, what works for me may not work for them.” Finally, one participant was in 
favour of micronutrients claiming that age should not be a factor of their use: “Regardless of 
age, we all need the vitamins and minerals we no longer get from our processed foods.”  
 As suggested by the analyses, the more accepting people are towards micronutrients 
as a treatment for mood disorders, the more likely they will be to accept people under the age 
of 18 using them. Ideally, adults accepting of alternative or conventional treatments should 
express this to adolescents in their lives, helping them to feel more comfortable in discussing 
treatment options with caregivers and thus be supervised during treatment. 
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Limitations and Directions for Future Research 
The largest limitation in the present study was the method of participant recruitment. Initially 
the entire psychology student body at the University of Canterbury was emailed with a link to 
the study survey. As research participation is a credit requirement for first year psychology 
students the majority of the sample were females in this year group. In an attempt to diminish 
the number of undergraduate female psychology students, participants were emailed from a 
pool who already had done a micronutrient study (Rucklidge, Johnstone, Harrison & Boggis, 
2011). This group may have had pre-formed opinions depending on their experiences with 
micronutrient treatments or more knowledge than other participants. Additionally there was 
an uneven distribution of participants across profession categories. This may have been due 
to recruitment of colleagues from the New Zealand College of Clinical Psychologists and the 
American Psychological Association in the hopes of gaining perspectives from healthcare 
and medical professionals.  
A major limitation in the study was the incorporation of CBT into the definition of 
‘conventional’ treatments. Participants were confused about whether to choose conventional 
treatments or micronutrient treatments as their first choice should they come to be diagnosed 
or re-diagnosed with a mood disorder. Many participants commented that they would choose 
‘conventional’ treatments to engage in talking therapy and/or CBT but would choose 
micronutrients over antidepressants. The same reasoning was also demonstrated by 
participants who chose ‘micronutrients’ as their first treatment option. In future it would be 
recommended to add a ‘combination’ answer option. This recommendation was additionally 
sought by participants as demonstrated in the comments section at the conclusion of the 
survey: “I really don't like the idea of lumping prescription medication, and CBT, counselling 
etc. into one category because they deal with mood disorders in completely different ways.” 
MICRONUTRIENT TREATMENT IN MOOD DISORDERS 
 
65 
 
“I might have answered differently to some questions if conventional talking therapies and 
conventional medications had been separated out.” 
There were possible limitations with the measure. Although the prediction that people 
leading ‘healthy lifestyles’ would be more accepting was confirmed by the analyses, only the 
‘General Health’ and ‘Physical Functioning’ sections of the SF-36 were used to calculate 
participants ‘healthy lifestyle’ score, possibly impacting results. Other health scales or the 
complete use of the SF-36 scale may have produced different ‘healthy lifestyle’ scores.  
There were limitations with the way in which particular questions were asked. Section 
six (questions 26-30) asked participants about their previous experience with mood disorders. 
The question asked participants if they had had any experience with a mood disorder, rather 
than if they had been diagnosed with one. This makes it difficult to deduce whether or not 
people in the ‘yes’ group had self-diagnosed mood disorders. This may have differed their 
acceptance towards micronutrients as a treatment than those who had been diagnosed with a 
mood disorder from a mental health practitioner. Participants in the ‘unsure’ group may have 
overlapped with ‘yes’ or ‘no’ groups.  
Some questions in sections eight, nine and ten were asked in a confusing or leading 
way. These sections were made up of Likert-scale questions based on participants’ 
acceptance towards the use of micronutrients as an alternative treatment for mood disorders 
leading to their ‘acceptance’ score calculations. Question 33.b states: ‘There are less adverse 
side effects when taking micronutrients to treat mood disorders than there are when using 
conventional medications.’ This may have been confusing or leading and better expressed by 
‘Taking micronutrients can have aversive side effects’.  
Question 34.e states: ‘I feel that using micronutrients is a good idea for everyday life 
but not for trying to treat a mood disorder.’ This double-barrelled statement may have caused 
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some confusion, as demonstrated by one participant: “This should be split up as I would 
disagree with the first section but agree with the second.”  
Finally, section 11 (questions 35 and 36) asked participants to choose their first 
treatment from conventional or micronutrients should they come to be diagnosed or re-
diagnosed with a mood disorder. As this question was based on a hypothetical situation, 
people who had not had any experience with mood disorders may have found it difficult to 
place themselves in such a situation. Additionally the question gave no indication on the 
severity or length of the mood disorder. This was confirmed in the comment section by a few 
participants: “Some questions I felt it difficult to answer because I kept thinking "well, it 
depends..." it depends on the severity and the length of time the individual has been dealing 
with their disorder.” “Since I had no mood disorders or know anyone that does.  I found it 
hard to imagine what I would do if I developed one.”  
Section 11 was followed by one similar, asking participants to what level they agree 
with people under the age of 18 using micronutrients as a treatment for mood disorders. As 
this section was structurally different to the one preceding it (asking which treatment they 
would choose first rather than how strongly they agreed/disagreed with the use of 
micronutrients) they were incomparable for statistical analyses.  
 Future research interest may include acceptance studies into micronutrient treatments 
for mood disorders in non-Western cultures to see if healthcare and medical practitioners’ 
acceptance increases. As demonstrated by Imanishi and colleagues in 1999, the high level of 
acceptance from Japanese doctors to CAM may reflect the local history and beliefs around 
alternative treatment, which may produce similar results for the present study. 
Additional research is important focussing on acceptance of under 18 year-olds to 
gain their perspectives on the use of micronutrients as a treatment for mood disorders. This 
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study touched on adult perspectives towards the use of micronutrients in under 18 year-olds, 
but it is important to know the feelings of such treatments from all potential users themselves.  
Finally it would be worthwhile gaining the attitudes of healthcare and medical 
practitioners alone into the micronutrient treatment of mood disorders.  
 
Conclusion 
A small number of interesting significant results were found in the present study. Healthcare 
and medical professionals were found to be less accepting of micronutrients as an alternative 
treatment for mood disorders than other professions and people who lead more healthy 
lifestyles were found to be more accepting than less healthy lifestyles. There were no 
significant effects of gender, experience with mood disorders or low household incomes. 
Results were consistent with previous literature concluding that older and more educated 
people are more accepting of alternative treatments (Yates et al. 2005). Results are limited 
due to overrepresentation of females and healthcare and medical professionals in the sample.  
Lack of higher female acceptance for micronutrient treatment may be based on 
alternative motives to males, physiology or previous diagnoses such as cancer. Females tend 
to use other forms of alternative treatments such as meditation and relaxation, possibly 
explaining current results.  
Lower acceptance towards micronutrients as an alternative treatment for mood 
disorders was found in healthcare and medical professionals. Patient wishes and medical 
practitioner training and attitudes all effect CAM referrals. Overall, non-Western medical 
practitioners are more likely to be accepting of alternative treatments and healthcare and 
medical practitioners need more training and education in the use of CAM. Lack of evidence-
based knowledge is a large predictor in healthcare and medical professional acceptance of 
alternative treatments, as replicated in the current study.  
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Acceptance towards micronutrients as an alternative treatment for mood disorders 
increases with people who regard health with high importance. This finding is consistent with 
previous research that acceptance increases with physical activity, fruit intake and a high 
fibre diet. Consistent results were also produced with healthy older age groups having higher 
acceptance levels.  
Experience with mood disorder was not a predictor of acceptance. People unsure of 
their experience with mood disorder were the most accepting group and participants largely 
wanted a combination of CBT and/or talking therapy and micronutrients as a treatment for 
mood disorders.  
Lower income was not associated with lower acceptance. Studies have confirmed that 
most CAM treatments are relatively cheap and that vitamins are an inexpensive way to gain 
vital nutrients for the human body (Johnson, Bernard & Funderberg, 2002). Higher accepting 
participants were more likely to be accepting of the use of micronutrients in individuals 18 
years or under with a mood disorder. Adults that are accepting of CAM need to portray this to 
under 18 year-olds and strict supervision must be given during their use.  
Participants are more likely to accept alternative treatments to mood disorders such 
as micronutrients if they are older and if treatments are in line with their beliefs. Treatment 
users and treatment providers alike seek more knowledge about the effectiveness of 
micronutrients; and acceptance of micronutrients as an alternative treatment to mood 
disorders is largely granted on the basis of a combination treatment with conventional 
methods. 
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Could multivitamins be 
the key to treating  
mood disorders?? 
 
 
 
We are looking for people over the age of 16 
to fill out a quick online survey to let us know 
what they think about using dietary vitamins, 
minerals and amino acids (also known as 
micronutrients) as a treatment for mood 
disorders.  
 
As a thank you for your time YOU COULD WIN ONE OF TWO 
2GIG IPODS personally engraved with whatever you choose! 
 
PLEASE VISIT  
http://canterbury.qualtrics.com/SE/?SID=SV
_9ntJcZOcPTImnHK and let us know 
what you think! 
 
 
 
 
 
 
This study has been approved by the University of Canterbury Human Ethics Committee. 
For more information please contact ged33@uclive.ac.nz. 
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Statement of Voluntary Consent 
To participate in the study described below 
   
 
Name of Study:  Acceptance Towards the Use of Micronutrients in the Treatment of Mood 
Disorders 
Purpose of Study:  To better understand the attitudes of the general public towards using 
micronutrients in treating mood disorders through the analysis of survey results; and make 
possible recommendations to general practitioners, people experiencing mood disorders, 
professionals in the psychology discipline, medication manufacturers and the general public. 
 Primary Researcher(s):  Dr. Julia Rucklidge, Grace McNatty 
Contact Information: Department of Psychology 
                                  University of Canterbury  
                                  Private Bag 4800  
                                  Christchurch 8140 
As a volunteer participant in the above mentioned research, I understand that I will be asked 
to complete a survey that will ask questions related to the use of micronutrients in mood 
disorders and my feelings towards this.  The survey typically takes about 15 minutes to 
complete although this time can vary depending on each participant.  I also understand that I 
may consider some of the questions personal in nature but that the information I provide will 
be used exclusively for this study and will in no way be associated with my name, computer 
log-in or any other identifiable information. 
As a participant in this study I am aware that the questions in this survey may cause anxiety 
or stress depending on my personal situation but that my answers may assist people 
experiencing mood disorders and possibly help give them more suitable options when 
considering treatment in future. 
By clicking “I Agree”, I state that I have read this consent form in its entirety and I 
understand that I may exit from this survey at any time without consequence. 
 
□ I AGREE 
□ I DO NOT AGREE 
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ACCEPTANCE TOWARD THE USE OF MICRONUTRIENTS IN THE 
TREATMENT OF MOOD DISORDERS: A SURVEY 
 
 
 
Section 1: Demographic 
 
Are you:  
Male  
Female  
 
What is your date of birth? (DD/MM/YYYY) 
NOTE: Participants under the age of 16 are unfortunately ineligible to complete this survey and will therefore 
automatically exit upon completion of this answer.  
 
What is your country of residence?  
 
 
What is your marital status?  
Married  
Divorced  
Separated  
Single  
De Facto  
Civil Union  
Widow  
 
Which ethnicity/ethnicity's do you most strongly identify yourself with? (Please select all that apply)  
 
New Zealand European  
 
Chinese  
 
Other European (Please Specify) 
  
Indian  
 
Maori  
 
Japanese  
 
Samoan  
 
Middle Eastern  
 
Cook Islands  
 
Latin American  
 
Tongan  
 
African  
 
Niuean  
 
Korean  
 
Fijian  
 
Don't Know  
 
Vietnamese  
 
Other (Please Specify)  
 
 
 
 
 
Section 2:Work and Income 
The following group of questions are based around your employment and income. 
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With regard to your most current or recent job activity: 
  
a) In what kind of industry do/did you work? (For example: hospital, newspaper publishing, mail room, factory 
work, engine manufacturing.) 
 
 
b) What kind of work do (did) you do? (Job Title - For example: registered nurse, personnel manager, 
supervisor of department, grinder operator etc.)  
 
 
What is the highest qualification you have earned?  
Final year of high school  
Apprenticeship certification  
Post Graduate Diploma  
Bachelor's Degree  
Master's Degree  
Doctorate  
None of the above (less than final year of high school)  
Other (Please specify)  
 
Which of the following best describes your main daily activities and/or responsibilities?  
Working full-time  
Working part-time  
Studying full-time  
Unemployed or laid off  
Looking for work  
Keeping house or raising children full-time  
Retired  
Other (Please specify)  
 
 
Roughly how much did you earn, before taxes and other deductions, over the last 12 months?  
Less than $5,000  
$5,000 through $11,999  
$12,000 through $15,999  
$16,000 through $24,999  
$25,000 through $34,999  
$35,000 through $49,999  
$50,000 through $74,999  
$75,000 through $99,999  
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$100,000 and greater  
Don't Know  
No Response  
 
Please state the currency in which this money was earned:  
 
 
Section 3: Household 
 
The following group of questions are based around your household. 
 
 
How many people are currently living in your household, including yourself?  
 
 
 
Of these people, how many are children?  
 
 
Of these people, how many are adults?  
 
 
Of the adults, how many bring income into the household?  
 
Section 4: General Health 
 
The following group of questions are based around your health. 
 
 
In general, would you say your health is:  
Excellent  
Very good  
Good  
Fair  
Poor  
 
Compared to one year ago, how would you rate your health in general now?  
Much better than one year ago  
Somewhat better now than one year ago  
About the same as one year ago  
Somewhat worse now than one year ago  
Much worse now than one year ago  
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The following items are about activities you might do during a typical day. 
 
Does your health limit you in these activities? If so, how much? 
  
  
     Yes, limited a lot  Yes, limited a little  No, not limited at all  
Vigorous activities, such as 
running, lifting heavy 
objects, participating in 
strenuous sports  
 
       
Moderate activities, such as 
moving a table, pushing a 
vacuum cleaner, bowling, 
or playing golf  
 
  
     
Lifting or carrying 
groceries  
 
        
Climbing several flights of 
stairs  
 
        
Climbing one flight of 
stairs  
 
        
Bending or kneeling          
Walking more than one 
kilometre (0.6 Miles)  
 
        
Walking several blocks    
     
Walking one block         
Bathing or dressing myself    
     
 
 
 
  
How true or false is each of the following statements for you? 
  
  
     Definitely False  Mostly False  Don't Know  Mostly True  Definitely True  
I seem to get sick a little 
easier than other people.  
 
                 
I am as healthy as anybody 
I know.  
 
                 
I expect my health to get 
worse.                   
My health is excellent.                   
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Please state the extent to which you agree or disagree with the following statements: 
  
  
     Strongly Disagree  Disagree  
Neither Agree 
nor Disagree  Agree  Strongly Agree  
There is nothing more 
important than good health.                  
 
Good health is only of 
minor importance in a 
happy life.  
                 
 
If you don't have your 
health, you don't have 
anything.  
                 
There are many things I 
care about more than my 
health.  
                 
Alternative Treatment 
Providers 
 
 
Section 5: Use of Alternative Treatments 
 
The following group of questions are based around alternative treatments for 
health care and your possible use of these. 
 
 
Which natural health products and therapies do you use or have you used in the past? (Please select all that 
apply)  
 
Acupuncture  
 
Transcendental Meditation  
 
Acupressure  
 
Music Therapy  
 
Aromatherapy  
 
Naturopathy  
 
Art therapy  
 
Osteopathy  
 
Ayurveda (Native traditional Indian medicine)  
 
Reiki (Japanese Spiritual Practice)  
 
Bach flower remedies  
 
Reflexology  
 
Chiropractic  
 
Relaxation/Breathing Technique  
 
Colour Therapy  
 
Shiatsu Massage  
 
Dance Movement Therapy  
 
Traditional Chinese Medicine  
 
Spiritual Healing  
 
Therapeutic Touch  
 
Herbal Medicine  
 
Visualisation  
 
Homeopathy  
 
Vitamins & Minerals  
 
Hypnosis  
 
Yoga  
 
Magnetic Therapy  
 
Other (Please Specify)  
 
Massage  
 
None of the above  
 
Meditation      
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Have you ever used alternative treatments for: (Please select all that apply)  
Preventing Illness  
Treating Illness  
Promoting Health  
I have NEVER used alternative treatments  
Other (Please Specify)  
 
 
Identify the statement that best describes your health care practices:  
I use alternative treatments only.  
I use alternative treatments alongside medical treatments given to me by my doctor.  
 
 
Identify the statement that best describes your intake of natural health products: 
  
NOTE: For the purpose of this survey 'natural health products' are defined as products that contain generally low 
risk ingredients that are derived from nature or their synthetic equivalents. 
I do not take natural health products.  
I take natural health products on a daily basis.  
I take natural health products on a weekly basis.  
I take natural health products on a monthly basis.  
I take natural health products once a year.  
I take natural health products less than once a year.  
Other (Please specify)  
 
 
Identify the statement that best describes your level of involvement with an alternative treatment provider:  
I do not see alternative treatment providers.  
I see alternative treatment providers on a daily basis.  
I see alternative treatment providers on a weekly basis.  
I see alternative treatment providers on a monthly basis.  
I see alternative treatment providers once a year.  
I see alternative treatment providers less than once a year.  
Other (Please specify)  
 
 
Section 6: History with mood disorders 
 
The questions that follow are going to revolve around mood disorders and your ideas about treating them. 
 
 
A mood disorder is defined as a Depressive disorder (including atypical depression, melancholic depression, 
psychotic major depression, catatonic depression, postpartum depression, seasonal affective disorder, dysthymia 
and/or depressive disorder not otherwise specified) or Bipolar disorder (including Bipolar I, Bipolar II, 
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cyclothymia and/or Bipolar disorder not otherwise specified). 
 
 
Have you ever experienced a mood disorder?  
Yes  
No  
Unsure  
 
 
Which type of mood disorder did you experience?  
A depressive disorder (including atypical depression, melancholic depression, psychotic major depression, 
catatonic depression, postpartum depression, seasonal affective disorder, dysthymia and/or depressive disorder 
not otherwise specified)  
Bipolar Disorder (including Bipolar I, Bipolar II, cyclothymia and/or Bipolar disorder not otherwise 
specified)  
 
 
Did you attempt to treat this mood disorder with a conventional treatment? 
 
(A conventional treatment is defined as any treatment for a mood disorder that is a form of psychotherapy, 
counselling, any kind of professional talking therapy and/or any prescribed medication, eg. antidepressants or 
anti psychotics.)  
Yes (Please specify)  
No  
 
If you did not use a conventional form of treatment, did you try any other form of treatment?  
No  
Yes (Please specify)  
Did not use ANY treatment  
 
 
Section 7: Likelihood of Alternative Treatments for Mood Disorders 
 
 
If you were to be diagnosed with a mood disorder how likely would you be to use the following treatments? 
  
  
NOTE: A mood disorder is defined as a Depressive disorder (including atypical depression, melancholic 
depression, psychotic major depression, catatonic depression, postpartum depression, seasonal affective 
disorder, dysthymia and/or depressive disorder not otherwise specified) or Bipolar disorder (including Bipolar I, 
Bipolar II, cyclothymia and/or Bipolar disorder not otherwise specified). 
  
  
     Very Unlikely  Unlikely  Undecided  Likely  Very Likely  
Antidepressant medications            
Anti-psychotic medications             
Cognitive behavioural 
therapy              
Family therapy              
Vitamins, minerals &             
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amino acids  
Group therapy              
Individual therapy              
Support groups              
Electroconvulsive therapy              
Acupuncture              
Massage therapy              
Yoga              
Light therapy              
Magnetic therapy    
         
Hypnosis              
Herbal medicine               
Breathing exercises               
 
 
 
 
Section 8: Micronutrient 
Acceptance 
  
  
The following group of questions are based around your attitudes to using 
micronutrients to treat mood disorders. 
  
  
For this section, select the box that best represents how much you agree or disagree with each statement. Please 
answer every question. 
 
For example, if you strongly disagreed with the statement "Camping is enjoyable", then next to this statement 
you would select "Strongly Disagree." 
  
 
For the purpose of this question please note the following definitions: 
 
Micronutrients are defined as dietary multivitamins, minerals and amino acids. 
 
Alternative treatments are defined as any treatment that is not a form of psychotherapy, counselling, 
professional talking therapy or any prescribed antidepressant or anti-psychotic medication. 
 
Conventional treatments are defined as any treatment for a mood disorder that is a form of psychotherapy, 
counselling, any kind of professional talking therapy and/or any prescribed medications (eg. antidepressants or 
anti-psychotics). 
 
A mood disorder is defined as a Depressive disorder (including atypical depression, melancholic depression, 
psychotic major depression,catatonic depression, postpartum depression, seasonal affective disorder, dysthymia 
and/or depressive disorder not otherwise specified) or Bipolar disorder (including Bipolar I, Bipolar II, 
cyclothymia and/or Bipolar disorder not otherwise specified). 
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     Strongly Disagree  Disagree  
Neither Agree 
nor Disagree  Agree  Strongly Agree  
People who fear the 
discomfort of traditional 
treatments for mood 
disorders from medical 
doctors are more likely to 
use micronutrients as an 
alternative treatment.  
 
           
Micronutrients as an 
alternative treatment for 
mood disorders are a threat 
to public health.  
 
  
         
Micronutrients as an 
alternative treatment for 
mood disorders should be 
included in clinical care.  
  
         
I feel that I do not know 
enough about 
micronutrients and how 
they work.  
 
           
Family and friends can 
influence a person's use of 
micronutrients as an 
alternative treatment to 
mood disorders by 
exposing them to it.  
 
            
Positive results found using 
micronutrients as an 
alternative treatment to 
mood disorders are most 
likely due to a placebo 
effect.  
 
  
         
Taking micronutrients as 
an alternative treatment for 
mood disorders is not 
harmful.  
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Section 9: Micronutrient 
Acceptance  Continued 
 
 
 
For the purpose of this question please note the following definitions: 
 
Micronutrients are defined as dietary multivitamins, minerals and amino acids. 
 
Alternative treatments are defined as any treatment that is not a form of psychotherapy, counselling, 
professional talking therapy or any prescribed antidepressant or anti-psychotic medication. 
 
Conventional treatments are defined as any treatment for a mood disorder that is a form of psychotherapy, 
counselling, any kind of professional talking therapy and/or any prescribed medications (eg. antidepressants or 
anti-psychotics). 
 
A mood disorder is defined as a Depressive disorder (including atypical depression, melancholic depression, 
psychotic major depression,catatonic depression, postpartum depression, seasonal affective disorder, dysthymia 
and/or depressive disorder not otherwise specified) or Bipolar disorder (including Bipolar I, Bipolar II, 
cyclothymia and/or Bipolar disorder not otherwise specified). 
  
  
  
     Strongly Disagree  Disagree  
Neither Agree 
nor Disagree  Agree  Strongly Agree  
Micronutrients contain 
natural formula's which are 
healthier than taking drugs 
given by a medical doctor.  
 
            
People who believe in the 
physical, mental and 
spiritual aspects of health 
are more likely to use 
micronutrients as an 
alternative form of mood 
disorder treatment.  
            
There are less adverse side 
effects when taking 
micronutrients to treat 
mood disorders than there 
are when using 
conventional medications.  
 
            
The more knowledge a 
person has about 
micronutrients, the more 
likely he/she would be to 
use it as an alternative 
treatment for mood 
disorders.  
 
  
         
I feel that using 
micronutrients alone to 
treat mood disorders is not 
ethical, i.e it infringes on 
the patient's rights.  
  
       
 
I would be more likely to   .        
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try micronutrients as an 
alternative treatment to 
mood disorders if it WAS 
popular rather than if it was 
NOT popular.  
 
If evidence showed that 
micronutrients were 
as equally effective as 
conventional medications, 
involving less side effects 
but involving more pill-
taking than conventional 
medications, I would try 
using micronutrients to 
treat my mood disorder.  
            
 
 
 
 
Section 10: Micronutrient Acceptance Continued 
  
 
 
For the purpose of this question please note the following definitions: 
 
Micronutrients are defined as dietary multivitamins, minerals and amino acids. 
 
Alternative treatments are defined as any treatment that is not a form of psychotherapy, counselling, 
professional talking therapy or any prescribed antidepressant or anti-psychotic medication. 
 
Conventional treatments are defined as any treatment for a mood disorder that is a form of psychotherapy, 
counselling, any kind of professional talking therapy and/or any prescribed medications (eg. antidepressants or 
anti-psychotics). 
 
A mood disorder is defined as a Depressive disorder (including atypical depression, melancholic depression, 
psychotic major depression,catatonic depression, postpartum depression, seasonal affective disorder, dysthymia 
and/or depressive disorder not otherwise specified) or Bipolar disorder (including Bipolar I, Bipolar II, 
cyclothymia and/or Bipolar disorder not otherwise specified). 
  
  
  
     Strongly Disagree  Disagree  
Neither Agree 
nor Disagree  Agree  Strongly Agree  
I view micronutrients as a 
worthwhile possible 
treatment for mood 
disorders.  
 
           
If I were to use 
micronutrients to treat my 
own mood disorder and 
found positive results, or if 
I were to witness others use 
micronutrients to treat their 
mood disorder and find 
positive results, I would be 
happy to recommend them 
to others.  
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I feel that using 
micronutrients is a good 
idea for everyday life but 
not for trying to treat a 
mood disorder.  
 
            
Micronutrient treatments 
used to treat mood 
disorders that have not 
been tested in a scientific 
manner should be 
discouraged.  
 
            
People would be more 
likely to use micronutrients 
to treat mood disorders if 
there were more stores that 
sold them.  
            
I would not mind taking 
micronutrients if I were to 
be diagnosed/re-diagnosed 
with a mood disorder and a 
general practitioner or 
other medical professional 
recommended that I do so.  
           
 
 
Section 11: Micronutrients vs 
Conventional for adults 
 
If micronutrients and conventional treatments were found to be equally effective for treating mood disorders and 
you came to be diagnosed with (or re-diagnosed with) a mood disorder, which treatment would you choose 
first? 
 
 
NOTE: Micronutrients are defined as dietary vitamins, minerals & amino acids. 
 
Conventional treatments are defined as any treatment for a mood disorder that is a form of psychotherapy, 
counselling, any kind of professional talking therapy and/or any prescribed antidepressant or anti-psychotic 
medication.  
Conventional treatments  
Micronutrients  
Other (Please specify)  
No treatment  
 
Why would this be your first chosen treatment?  
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Section 12: Micronutrients vs Conventional for Under 18 
 
If micronutrients and conventional treatments were found to be equally effective for treating mood disorders and 
someone you knew under the age of 18 came to be diagnosed with a mood disorder, would you agree with them 
using micronutrients as a treatment? 
 
 
NOTE: Micronutrients are defined as dietary vitamins, minerals & amino acids. 
 
Conventional treatments are defined as any treatment for a mood disorder that is a form of psychotherapy, 
counselling, any kind of professional talking therapy and/or any prescribed antidepressant or anti-psychotic 
medication.  
I would strongly disagree  
I would disagree  
I would neither disagree nor agree  
I would agree  
I would strongly agree  
 
Why would you react in this way?  
 
 
 
 
Comments: 
If you have any questions or comments about this survey, please feel free to express them here: 
 
 
 
 
 
 
 
 
 
Survey Powered By Qualtrics 
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Table 5 
Male Summary of Results 
 
Participant 
Information 
 
N= 
 
Average 
Healthy 
Lifestyle 
Score* 
 
Average 
Acceptan
ce Score 
**** 
 
First Treatment 
Choice (%) 
 
Average 
Acceptanc
e of Under 
18s 
Use*** 
 Mic
ron
utri
ent 
Con
vent
iona
l 
Ot
her 
N
on
e 
 
 
Age 
        
18-32 84 
(59.6%) 
60.9 67.6 26.2 47.6 7.1 2.4 3.4 
33-46 25 
(17.7%) 
59.6 71.2 8.0 64.0 24.
0 
16.
0 
3.6 
47-60 29 
(20.6%) 
61.9 69.3 17.2 72.4 10.
3 
0.0 3.6 
61-74 3 (2.1%) 59.0 65.3 0.0 33.3 66.
7 
0.0 2.7 
Mean  60.4 68.4 12.9 54.3 27.
0 
4.6 3.3 
 
Country of Residence 
NZ 113 
(80.1%) 
60.2 68.2 31.9 54.0 12.4 1.8 3.5 
Australia 7 (5.0%) 61.2 68.0 50.0 50.0 0.0 0.0 3.2 
USA 19 
(13.5%) 
64.0 71.4 21.1 63.2 10.5 5.3 3.2 
China - - - - - - - - 
Belgium 1 (0.7%) 63.0 61.0 0.0 100.
0 
0.0 0.0 4.0 
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Kuwait - - - - - - - - 
Russia - - - - - - - - 
UAE 1 (0.7%) 68.0 72.0 0.0 0.0 100.
0 
0.0 4.0 
Vietnam - - - - - - - - 
Malaysia - - - - - - - - 
India - - - - - - - - 
France - - - - - - - - 
Mean  63.3 68.1 20.6 53.4 24.6 1.4 3.6 
 
Primary Ethnicity 
NZ European 103 
(73.0%) 
60.6 69.2 33.0 54.4 9.7 2.9 3.5 
Other 
European 
23 
(16.3%) 
61.1 66.4 26.1 73.9 21.7 0.0 3.0 
Maori 1 (0.7%) 50.0 64.0 100.
0 
0.0 0.0 0.0 3.0 
Samoan - - - - - - - - 
Vietnamese - - - - - - - - 
Chinese 1 (0.7%) 57.0 65.0 100.
0 
0.0 0.0 0.0 4.0 
Indian 1 (0.7%) 68.0 72.0 0.0 0.0 100.
0 
0.0 4.0 
Middle 
Eastern 
- - - - - - - - 
Latin 
American 
- - - - - - - - 
African - - - - - - - - 
Korean 2 (1.4%) 62.5 65.0 0.0 100.
0 
0.0 0.0 4.0 
Don’t Know 2 (1.4%) 64.0 65.0 50.0 50.0 0.0 0.0 2.5 
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Other 8 (5.7%) 63.0 69.1 0.0 87.5 12.5 0.0 4.0 
Mean  60.8 67.0 38.6 45.7 18.0 0.4 3.5 
 
Highest Qualification 
Final Year of 
High School 
52 
(36.9%) 
58.6 67.4 34.6 51.9 11.5 1.9 3.5 
Apprenticesh
ip 
Certification 
9 (6.4%) 63.9 71.0 22.2 66.7 11.1 0.0 3.4 
Post 
Graduate 
Diploma 
9 (6.4%) 68.0 78.7 11.1 77.8 11.1 0.0 3.4 
Bachelor’s 
Degree 
25 
(17.7%) 
62.6 68.4 40.0 48.0 8.0 4.0 3.6 
Master’s 
Degree 
22 
(15.6%) 
61.7 68.4 27.3 54.5 18.2 0.0 3.3 
Doctorate 14 
(9.9%) 
59.6 65.1 28.6 50.0 21.4 0.0 3.4 
Less Than 
Final Year of 
High School 
4 (2.8%) 55.0 61.0 50.0 50.0 0.00 0.0 3.25 
Other 6 (4.3%) 61.2 74.0 0.0 83.3 0.0 16.
7 
3.3 
Mean  61.3 69.3 26.7 60.3 10.2 2.8 3.4 
 
Annual Income ($NZ) 
Less than 
5,000 
17 
(12.1%) 
57.5 65.6 52.9 41.2 0.0 5.9 2.9 
5,000-11,999 29 
(20.6%) 
59.1 69.1 37.9 51.7 10.3 0.0 3.5 
12,000-
15,999 
6 (4.3%) 59.0 64.5 33.3 50.0 16.7 0.0 3.3 
16,000- 18 62.1 69.3 38.9 44.4 11.1 5.6 3.4 
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24,999 (12.8%) 
25,000-
34,999 
6 (4.3%) 59.5 69.7 16.7 66.7 16.7 0.0 3.7 
35,000-
49,999 
11 
(7.8%) 
65.0 72.7 18.2 72.7 0.0 9.1 4.3 
50,000-
74,999 
20 
(14.2%) 
61.0 70.2 25.0 55.0 20.0 0.0 3.6 
75,000-
99,999 
12 
(8.5%) 
63.6 68.7 8.3 66.7 25.0 0.0 3.2 
100,000 or 
more 
11 
(7.8%) 
61.8 68.0 27.3 63.6 9.1 0.0 3.4 
Don’t Know 6 (4.3%) 62.5 66.0 16.7 83.3 0.0 0.0 3.2 
No Response 5 (3.5%) 61.0 64.6 20.0 40.0 40.0 0.0 3.4 
Mean  61.1 68.0 26.8 57.8 13.5 1.9 3.4 
 
Average “Healthy Lifestyle Score” (Out of 80) 
Lowest 
Quartile (42-
60) 
35 
(24.8%) 
- 67.8 37.4 45.7 17.1 0.0 3.3 
Second 
Lowest 
Quartile (60-
66) 
35 
(24.8%) 
- 69.2 34.3 54.3 8.6 2.9 3.6 
Second 
Highest 
Quartile (66-
69) 
35 
(24.8%) 
- 67.0 31.4 51.4 14.3 2.9 3.4 
Highest 
Quartile (69-
80) 
36 
(25.6%) 
- 73.0 19.4 69.4 8.3 2.7 3.4 
Mean   69.25 30.6 55.2 12.1 2.1 3.4 
 
Use Of Alternative Treatments 
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Used 
alternative 
treatments 
for: 
preventing 
illness, 
treating 
illness, 
promoting 
health, other. 
86 
(61.0%) 
60.6 70.2 22.1 61.6 15.1 1.2 3.5 
Never used 
alternative 
treatment. 
55 
(39.0%) 
 
61.1 
 
66.1 43.6 45.5 7.3 3.6 3.3 
 
Mean  60.9 68.2 32.9 53.6 11.2 2.4 3.4 
 
For those who have used Alternative Treatments (as previous): 
Use only 
Alternative 
Treatments 
4 (4.7%) 59.0 76.5 25.0
0 
50.0 25.0 0.0 3.3 
Use 
Alternative 
Treatments 
Alongside 
Conventional 
Treatments 
82 
(95.3%) 
60.7 69.8 22.0 62.2 14.6 1.2 3.5 
Mean  59.9 73.2 23.5 56.1 19.8 0.6 3.4 
 
Type of Previous Alternative Treatments use 
Acupuncture 36 
(5.7%) 
59.4 70.9 11.1 61.1 25.0 2.8 3.3 
Acupressure 15 
(2.4%) 
63.5 66.3 6.7 66.7 26.7 0.0 3.3 
Aromatherap
y 
17 
(2.7%) 
60.2 70.2 23.5 58.5 17.6 0.0 3.4 
Art Therapy 9 (1.4%) 61.7 73.2 22.2 44.4 33.3 0.0 3.3 
Ayurveda 3 (0.5%) 61.0 76.7 0.0 33.3 66.7 0.0 4.3 
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Bach Flower 
Remedies 
7 (1.1%) 57.6 69.9 14.3 71.4 14.3 0.0 3.3 
Chiropractic 37 
(5.9%) 
60.4 70.4 5.4 73.0 21.6 0.0 3.6 
Colour 
Therapy 
3 (0.5%) 60.7 67.0 33.3 33.3 33.3 0.0 4.3 
Dance 
Movement 
Therapy 
1 (0.2%) 73.0 89.0 0.0 100.
0 
0.0 0.0 1.0 
Spiritual 
Healing 
12 
(1.9%) 
57.3 72.1 8.3 66.7 25.0 0.0 2.8 
Herbal 
Medicine 
37 
(5.9%) 
61.2 73.6 2.7 81.1 16.2 0.0 3.5 
Homeopathy 16 
(2.5%) 
58.7 70.8 12.5 50.0 37.5 0.0 3.2 
Hypnosis 12 
(1.9%) 
58.5 70.8 0.0 75.0 25.0 0.0 3.1 
Magnetic 
Therapy 
5 (0.8%) 51.8 71.6 20.0 40.0 40.0 0.0 2.8 
Massage 78 
(12.4%) 
62.0 70.8 20.5 64.1 14.1 1.3 3.5 
Meditation 51 
(8.1%) 
61.8 70.5 23.5 54.9 21.6 0.0 3.5 
Transcendent
al Meditation 
13 
(2.1%) 
59.0 69.7 23.1 69.2 7.7 0.0 3.4 
Music 
Therapy 
10 
(1.6%) 
63.5 72.6 20.0 60.0 20.0 0.0 3.3 
Naturopathy 20 
(3.2%) 
61.6 72.5 15.0 60.0 25.0 0.0 3.5 
Osteopathy 19 
(3.0%) 
60.6 67.0 10.5 42.1 42.1 5.3 3.2 
Reiki 13 
(2.1%) 
58.9 67.0 7.7 46.2 46.2 0.0 2.8 
Reflexology 14 
(2.2%) 
60.0 72.1 0.0 64.3 35.7 0.0 3.0 
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Relaxation/B
reathing 
Techniques 
43 
(6.8%) 
62.6 70.8 23.3 53.5 23.3 0.0 3.3 
Shiatsu 
Massage 
7 (1.1%) 56.3 70.0 0.0 71.4 28.6 0.0 2.9 
Traditional 
Chinese 
Medicine 
15 
(2.4%) 
60.3 72.2 6.7 73.3 13.3 6.7 3.4 
Therapeutic 
Touch 
5 (0.8%) 60.4 71.0 0.0 80.0 20.0 0.0 3.2 
Visualisation 19 
(3.0%) 
58.5 66.4 26.3 26.3 47.4 0.0 3.3 
Vitamins & 
Minerals 
77 
(12.2%) 
60.9 71.2 20.8 66.2 13.0 0.0 3.5 
Yoga 35 
(5.6%) 
62.9 69.4 28.6 45.7 22.9 2.9 3.4 
Mean  60.5 71.2 13.3 59.7 26.3
0 
0.7 3.3 
 
Previous Experience With Mood Disorder 
Yes – 
Depression 
49 
(34.8%) 
60.7 68.4 34.7 42.9 20.4 2.0 3.3 
Yes – Bipolar 3 (2.1%) 61.0 80.3 0.0 100.
0 
0.0 0.0 3.3 
No 67 
(47.5%) 
61.1 68.3 31.3 58.2 7.5 3.0 3.4 
Unsure 22 
(15.6%) 
60.2 68.1 22.7 68.2 9.1 0.0 3.6 
Mean  60.8 71.3 22.2 67.3 9.3 1.3 3.4 
 
If yes to Mood Disorder was Treatment Attempted using a Conventional Treatment? 
Yes 34 
(65.4%) 
61.3 68.9 44.1 41.2 11.8 2.9 3.6 
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No 18 
(34.6%) 
61.8 67.3 22.2 66.7 11.1 0.0 3.5 
Mean  61.6 68.1 33.2 54.0 11.5 1.5 3.6 
 
If no to Conventional Treatment was any other form of Treatment used? 
Yes** 5 
(27.8%) 
63.6 64.0 40.0 60.0 0.0 0.0 3.4 
No 13 
(72.2%) 
61.2 68.5 15.4 69.2 15.4 0.0 3.5 
Mean  62.4 66.3 27.7 64.6 7.7 0.0 3.5 
 
*Out of Possible 80 
**Followed by specific treatment answers 
***Out of Possible 5 
****Out of a Possible 100 
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Table 6 
Female Summary of Results 
 
Participant 
Information 
 
N= 
 
Average 
Healthy 
Lifestyle 
Score** 
 
Average 
Acceptance 
Score**** 
 
First Treatment Choice 
(%) 
 
 
 
Average 
Acceptance 
of Under 
18s Use*** 
Micr
onut
rient 
Con
venti
onal 
Othe
r 
No
ne 
 
Age 
        
18-32 298 
(57.3%) 
60.7 69.7 36.9 52.7 7.4 2.7 3.5 
33-46 111 
(21.3%) 
62.1 70.6 24.3 64.9 9.9 0.9 3.9 
47-60 91 
(17.5%) 
63.0 70.1 20.9 61.5 15.4 2.2 3.9 
61-74 20 (3.8%) 59.8 70.3 25.0 50.0 15.0 0.0 3.8 
Mean  61.4 70.2 26.8 57.3 11.9 1.5 3.8 
 
Country of Residence 
NZ 443 
(85.2%) 
61.1 70.6 29.8 59.1 9.3 1.8 3.7 
Australia 10 (1.9%) 62.0 70.2 60.0 40.0 0.0 0.0 3.4 
USA 59 
(11.3%) 
63.1 66.2 42.4 44.1 11.9 1.7 3.2 
China 2 (0.4%) 63.0 62.5 0.0 50.0 0.0 50.
0 
2.5 
Belgium - - - - - - - - 
Kuwait 1 (0.2%) 64.0 75.0 0.0 100.
0 
0.0 0.0 1.0 
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Russia 1 (0.2%) 59.0 51.0 0.0 100.
0 
0.0 0.0 4.0 
UAE - - - - - - - - 
Vietnam 1 (0.2%) 59.0 67.0 0.0 0.0 100.
0 
0.0 3.0 
Malaysia 1 (0.2%) 58.0 66.0 0.0 0.0 0.0 10
0.0 
3.0 
India 1 (0.2%) 62.0 64.0 100.
0 
0.0 0.0 0.0 4.0 
France 1 (0.2%) 60.0 70.0 0.0 100.
0 
0.0 0.0 5.0 
Mean  61.1 66.3 23.2 49.3 12.1 15.
4 
3.3 
 
Primary Ethnicity 
NZ European 387 
(74.4%) 
61.1 70.6 30.0 59.4 9.3 1.3 3.7 
Other 
European 
95 
(18.3%) 
62.3 68.4 35.8 49.5 11.6 3.2 3.5 
Maori 7 (1.3%) 58.4 67.7 14.3 71.4 0.0 14.
3 
3.4 
Samoan 1 (0.2%) 66.0 81.0 100.
0 
0.0 0.0 0.0 5.0 
Vietnamese 1 (0.2%) 59.0 67.0 0.0 0.0 100.
0 
0.0 3.0 
Chinese 12 (2.3%) 60.7 68.3 41.7 33.3 8.3 16.
7 
3.1 
Indian 2 (0.4%) 55.0 63.5 100.
0 
0.0 0.0 0.0 4.0 
Middle 
Eastern 
1 (0.2%) 70.0 73.0 0.0 100.
0 
0.0 0.0 3.0 
Latin 
American 
4 (0.8%) 65.3 67.8 25.0 75.0 0.0 0.0 3.5 
African 3 (0.6%) 64.0 66.3 33.3 66.7 0.0 0.0 3.3 
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Korean 1 (0.2%) 67.0 71.0 0.0 100.
0 
0.0 0.0 4.0 
Don’t Know 3 (0.6%) 61.7 64.3 100.
0 
0.0 0.0 0.0 4.0 
Other 3 (0.6%) 63.7 73.3 0.0 100.
0 
0.0 0.0 3.3 
Mean  62.6 69.4 36.9 50.4 9.9 2.7 3.6 
 
Highest Qualification 
Final Year of 
High School 
148 
(28.5%) 
59.1 70.4 29.7 60.1 4.7 5.4 3.6 
Apprenticesh
ip 
Certification 
7 (1.3%) 60.9 68.4 28.6 57.1 14.3 0.0 3.3 
Post 
Graduate 
Diploma 
59 
(11.3%) 
62.3 71.4 32.2 55.9 10.2 1.7 3.8 
Bachelor’s 
Degree 
109 
(21.0%) 
62.0 71.0 28.4 57.8 12.8 0.9 3.6 
Master’s 
Degree 
105 
(20.2%) 
63.0 69.6 31.4 56.2 11.4 1.0 3.8 
Doctorate 74 
(14.2%) 
62.0 66.6 43.2 45.9 10.8 0.0 3.5 
Less Than 
Final Year of 
High School 
5 (1.0%) 55.4 
 
77.8 0.0 80.0 20.0 0.0 4.4 
Other 13 (2.5%) 61.8 70.3 23.1 76.9 0.0 0.0 3.3 
Mean  60.8 70.7 27.1 61.2 10.5 1.1 3.7 
 
Annual Income ($NZ) 
Less than 
5,000 
76 
(14.6%) 
58.9 70.5 28.9 61.8 3.9 5.3 3.5 
5,000-11,999 75 60.8 70.5 38.7 54.7 6.7 0.0 3.7 
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(14.4%) 
12,000-
15,999 
31 (6.0%) 58.9 73.5 29.0 61.3 6.5 3.2 3.7 
16,000-
24,999 
54 
(10.4%) 
61.1 69.6 20.4 64.8 9.3 5.6 3.4 
25,000-
34,999 
38 (7.3%) 62.6 71.5 26.3 65.8 5.3 2.6 3.8 
35,000-
49,999 
55 
(10.6%) 
61.7 70.6 25.5 61.8 12.7 0.0 3.9 
50,000-
74,999 
83 
(16.0%) 
62.8 69.3 37.3 54.2 8.4 0.0 3.8 
75,000-
99,999 
45 (8.7%) 62.1 67.1 35.6 55.6 8.9 0.0 3.7 
100,000 or 
more 
26 (5.0%) 64.5 69.0 34.6 34.6 26.9 3.8 3.5 
Don’t Know 22 (4.2%) 62.9 69.0 31.8 45.5 18.2 4.5 3.6 
No Response 15 (2.9%) 59.7 69.4 40.0 40.0 20.0 0.0 3.2 
Mean  61.5 70.0 31.6 54.6 11.5 2.3 3.6 
 
Average “Healthy Lifestyle Score” (Out of 80) 
Lowest 
Quartile (37-
60) 
130 
(24.8%) 
- 71.4 36.2 51.5 12.3 1.5 3.6 
Second 
Lowest 
Quartile (60-
65) 
130 
(24.8%) 
- 70.8 34.6 51.5 8.6 2.9 3.6 
Second 
Highest 
Quartile (65-
69) 
130 
(24.8%) 
- 72.0 27.7 59.2 10.8 2.3 3.8 
Highest 
Quartile (69-
80) 
130 
(25.6%) 
- 72.9 27.7 65.4 4.6 2.3 3.7 
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Mean   71.8 31.6 56.9 9.1 2.3 3.7 
 
Use Of Alternative Treatments 
Used 
alternative 
treatments 
for: 
preventing 
illness, 
treating 
illness, 
promoting 
health, other. 
399 
(76.7%) 
61.4 70.6 30.1 59.1 10.3 0.5 3.7 
Never used 
alternative 
treatment. 
121 
(23.3%) 
61.2 68.1 36.4 49.6 6.6 7.4 3.4 
Mean  61.3 69.4 33.3 54.4 8.5 4.0 3.6 
 
For those who have used Alternative Treatments (as previous): 
Use only 
Alternative 
Treatments 
19 (4.8%) 
 
61.9 73.3 10.5 89.5 0.0 0.0 3.6 
Use 
Alternative 
Treatments 
Alongside 
Conventional 
Treatments 
380 
(95.2%) 
61.4 70.4 31.1 57.6 10.8 0.5 3.7 
Mean  61.7 71.9 20.8 73.6 5.4 0.3 3.7 
 
Type of Previous Alternative Treatment use 
Acupuncture 150 
(5.0%) 
61.9 71.9 26.7 60.0 12.7 0.7 3.9 
Acupressure 62 (2.1%) 61.4 72.9 29.0 54.8 16.1 0.0 3.9 
Aromatherap
y 
147 
(4.9%) 
62.0 72.7 24.5 65.3 9.5 0.7 3.9 
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Art Therapy 32 (1.1%) 58.9 69.7 9.4 71.9 18.8 0.0 3.9 
Ayurveda 23 (0.8%) 62.8 74.7 4.3 73.9 21.7 0.0 4.1 
Bach Flower 
Remedies 
113 
(3.8%) 
61.2 73.1 19.5 65.5 14.2 0.9 4.0 
Chiropractic 122 
(4.1%) 
60.7 71.9 30.4 67.9 9.8 0.9 3.8 
Colour 
Therapy 
12 (0.4%) 58.7 71.9 8.3 50.0 41.7 0.0 4.2 
Dance 
Movement 
Therapy 
25 (0.8%) 60.5 72.9 4.0 72.0 20.0 16.
0 
3.6 
Spiritual 
Healing 
47 (1.6%) 60.5 73.0 27.7 59.6 12.8 0.0 3.8 
Herbal 
Medicine 
165 
(5.5%) 
61.2 72.4 18.2 66.7 13.9 1.2 3.8 
Homeopathy 136 
(4.5%) 
61.9 71.8 27.2 65.4 6.6 0.7 3.8 
Hypnosis 36 (1.2%) 63.2 73.5 16.7 72.2 11.1 0.0 3.9 
Magnetic 
Therapy 
19 (1.6%) 59.2 73.8 15.8 68.4 15.8 0.0 3.8 
Massage 314 
(10.4%) 
62.1 71.1 29.3 59.2 10.5 1.0 3.8 
Meditation 194 
(6.5%) 
61.8 70.8 30.4 55.2 13.9 0.5 3.8 
Transcendent
al Meditation 
21 (0.7%) 61.4 71.9 33.3 52.4 14.3 0.0 3.9 
Music 
Therapy 
28 (0.9%) 60.6 71.9 7.1 78.6 10.7 3.6 3.5 
Naturopathy 84 (2.8%) 61.4 74.5 14.3 69.0 15.5 1.2 4.2 
Osteopathy 115 
(3.8%) 
62.2 71.6 20.9 64.3 13.9 0.9 4.0 
Reiki 60 (2.0%) 61.6 72.2 21.7 61.7 16.7 0.0 4.0 
Reflexology 59 (2.0%) 61.5 73.6 30.5 55.9 13.6 0.0 4.2 
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Relaxation/B
reathing 
Techniques 
213 
(7.1%) 
61.7 70.1 34.3 50.7 14.6 0.5 3.8 
Shiatsu 
Massage 
29 (1.0%)  63.3 71.3 20.7 62.1 17.2 0.0 4.0 
Traditional 
Chinese 
Medicine 
39 (1.3%) 62.2 72.5 12.8 64.1 23.1 0.0 3.8 
Therapeutic 
Touch 
28 (0.9%) 62.9 75.6 25.0 50.0 25.0 0.0 3.9 
Visualisation 85 (2.8%) 62.8 70.6 30.6 54.1 15.3 0.0 3.6 
Vitamins & 
Minerals 
371 
(12.3%) 
61.1 70.7 28.0 61.5 9.4 1.1 3.7 
Yoga 277 
(9.2%) 
62.3 70.8 31.0 58.5 9.7 0.7 3.7 
Mean  61.5 72.3 21.8 62.4 15.5 1.1 3.9 
 
Previous Experience With Mood Disorder 
Yes – 
Depression 
195 
(37.5%) 
59.7 69.7 31.3 52.3 13.8 2.6 3.6 
Yes – Bipolar 4 (0.8%) 54.3 65.8 0.0 75.0 25.0 0.0 3.8 
No 259 
(49.8%) 
63.0 69.7 33.6 59.8 4.6 1.9 3.7 
Unsure 62 
(11.9%) 
60.2 72.3 25.8 58.1 14.5 1.6 3.5 
Mean  59.3 69.4 22.7 61.3 14.5 1.5 3.7 
 
If yes to Mood Disorder was Treatment Attempted using a Conventional Treatment? 
Yes 156 
(78.4%) 
59.3 70.1 30.8 51.9 16.0 1.3 3.7 
No 43 
(21.6%) 
60.4 68.1 30.2 55.8 7.0 7.0 3.6 
Mean  59.9 69.1 30.5 53.9 11.5 4.2 3.7 
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If no to Conventional Treatment was any other form of Treatment used? 
Yes** 9 (20.9%) 63.3 73.3 33.3 66.7 0.0 0.0 3.9 
No 34 
(79.1%) 
59.6 66.7 29.4 52.9 8.8 8.8 3.5 
Mean  61.5 70.0 31.4 59.8 4.4 4.4 3.7 
 
*Out of Possible 80 
**Followed by specific treatment answers 
***Out of Possible 5 
****Out of a Possible 100 
 
 
  
 
